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ABSTRACT

INNOVATIVE APPROACHES WITH OCULAR PHOTOCHEMISTRY:
FROM NON-INVASIVE DIAGNOSTIC TOOLS TO DRUG DELIVERY
Devi Kalyan Karumanchi, Ph.D.
Department of Chemistry and Biochemistry
Northern Illinois University, 2015
Elizabeth R. Gaillard, Director

Diabetes mellitus is an endocrinal metabolic disorder characterized by high blood sugar levels
which gives rise to complications in various organs of the body. Formation of advanced glycation
endproducts is universally considered a biomarker for diabetes. Currently, there are several
methods used for the diagnosis of diabetes – A1C, FPG and OGT tests. These methods are based
on screening the glycation of hemoglobin. Although, these tests give accurate results in diabetic
patients, they have their exceptions. One major disadvantage of measuring blood sugar levels is
the hemoglobin turnover, which is faster in case of diabetics and hence is a major disadvantage for
diagnosing the patients in their early stages. An early diagnosis would give the patient a chance
for intervention by following a diet and exercise regimen to delay the further complications that
arise due to diabetes. Therefore, in this work, the biomarkers for diabetes have been investigated
and quantified to develop a non-invasive diagnostic tool for diabetes.
Recent studies have shown the effect of AGE formation on the vasculature as well as its potential
role in several degenerative diseases. Alpha crystallin is a small heat shock protein found in the
lens. It is made of 2 sub-units- αA and αB. While αA is confined to the lens and retina, αB is found
ubiquitously in the body. αB sub-units have been shown to express under stress conditions
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throughout the body. Currently, several research groups are studying the implications of alpha
crystallin in diseases like cancer and neurodegenerative diseases. The biochemistry of diabetes,
microvascular pathology and neurodegenerative diseases is very similar with respect to formation
of AGEs, aggregation and development of hypoxic conditions. Our work dealt with studying the
effect of structural changes on the spectroscopic properties of the protein.
Ocular diseases mainly age-related macular degeneration (AMD), diabetic retinopathy (DR),
cataract and glaucoma are the leading causes of blindness in the world. Ocular drug delivery is a
major challenge due to the unique anatomy and physiology of the eye. Ocular barriers can be
classified into two types: Static tissue barriers which comprise of different layers of cornea, sclera,
and retina including blood aqueous and blood–retinal barriers; Dynamic barriers which are
physiological clearance mechanisms that comprise of tears, choroidal and conjunctival blood flow,
lymphatic clearance, and tear dilution. All these barriers cause a decrease in bioavailability of the
drug especially to the posterior segment.
Conventional ocular drug delivery through eye drops is complicated due to the barriers mentioned
above. About 95% of the drug is washed away by the tears. The next barrier is corneal permeability
where the corneal epithelium and the stroma selectively allow the hydrophobic and the hydrophilic
drugs respectively to pass through. After bypassing all the barriers, the drug that reaches the target
site is about 0.01% of original concentration and is not sufficient for the therapeutic action. As a
result, the dose frequency has to be increased. Therefore, it is necessary to develop timed/
sustained-release drug delivery systems which can efficiently deliver the drugs to the target site
without toxicity.
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CHAPTER I - GENERAL INTRODUCTION
Diabetes Mellitus
Diabetes mellitus is an endocrinal metabolic disorder characterized by a group of diseases that
affect how the body utilizes blood glucose, commonly called blood sugar. Diabetes mellitus is
classified into: type 1, type 2 and gestational diabetes (Greenspan, Gardner, & Shoback, 1997).
Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the islets of
Langerhans in the pancreas leading to insulin deficiency. This type of diabetes can be further
classified as immune-mediated or idiopathic. The majority of type 1 diabetes is of the immunemediated nature, in which a T-cell-mediated autoimmune attack leads to the loss of beta cells and
thus insulin (Rother, 2007). Type 2 diabetes mellitus is characterized by insulin resistance, which
may be combined with relatively reduced insulin secretion (Greenspan et al., 1997). The defective
responsiveness of body tissues to insulin is believed to involve the insulin receptor. However, the
specific defects are not known. Type 2 diabetes is the most common type.
Type 2 diabetes is primarily due to lifestyle factors and genetics (Risérus, Willett, & Hu, 2009). A
number of lifestyle factors are known to be important to the development of type 2 diabetes,
including obesity, lack of physical activity, poor diet, and stress (Larson, 1999). In the early stage
of type 2, the predominant abnormality is reduced insulin sensitivity. At this stage, hyperglycemia
can be reversed by a variety of measures and medications that are available that improve insulin
sensitivity or reduce glucose production by the liver.
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High blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia
(increased thirst) and polyphagia (increased hunger). The number of people with diabetes is
increasing due to population growth, aging, and increasing prevalence of obesity and lack of
physical activity. Untreated or undiagnosed diabetes can cause many complications. Acute
complications include diabetic keto-acidosis and hyper-osmolar coma. Serious long-term
complications include cardiovascular disease (diabetic cardiomyopathy), chronic renal failure
(diabetic nephropathy), loss of sensitivity (diabetic neuropathy) and retinal damage (diabetic
retinopathy). Thus control and treatment of diabetes through intervention at an early stage is very
important.
Maillard reaction
Maillard reaction is a chemical reaction between amino acids and sugars leading to condensation
products. In the body, reducing sugars and/or carbonyl intermediates react with free basic amino
groups on the side chains of arginine and lysine to form advanced glycation end products (AGEs).
These adducts accumulate in proteins, lipids, and nucleic acids (Ellis, 1959; Virovets, 1988). The
Maillard reaction plays an important role in diabetes and age-related dysfunction of the eye. The
pathogenesis of diabetes related disorders are multifactorial and it has been hypothesized that
glycation plays a significant role in cell and tissue dysfunction. Free radical generation seen in
aging and diabetes has been reported as a secondary consequence of Maillard chemistry (Kristal
& Byung, 1992).
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The chemistry of the Maillard reaction has always been one of the most challenging studies due to
its extreme complexity. Elucidating the structure of Maillard products bound to macromolecules
is very difficult due to the formation of extensive crosslinks. Although the structures of a number
of Maillard products have been elucidated in vitro, the exact compounds that are formed in vivo
are still debatable. A few of the AGEs that are formed by reaction of glucose and methylglyoxal
with basic amino acids have been reported in the literature are shown in Fig. 1 and 2 respectively.
The Maillard reaction gives rise to specific biomarkers on the proteins that have been observed in
diabetes as well as different neurodegenerative diseases that exhibit protein aggregation, such as
Alzheimer's disease, Pick's disease, Parkinson's disease, dementia with Lewy bodies, CreutzfeldtJakob disease, and amyotrophic lateral sclerosis (Nicholl et al., 1998; Sasaki et al., 1998; A. W.
Stitt, 2001; Alan W Stitt, 2005). Research shows that that glycation induces oxidative stress,
homeostasis, changes in mitochondrial function and energy metabolism. These particular
pathways have been reported to be the precursors for disease-specific patterns of protein molecular
damage (Beal, 1995; Forbes, Coughlan, & Cooper, 2008; Rolo & Palmeira, 2006). Overall,
previous literature suggests that the formation of advanced glycation endproducts due to Maillard
reaction can be used as a standard for studying the non-enzymatic glycation observed in diabetes,
aging and neurodegenerative diseases.
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Figure 1– Maillard reaction due to reaction of glucose with amino acids
(Bohlender, Franke, Stein, & Wolf, 2005)
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Figure 2-Methyl glyoxal derived advanced glycation endproducts
(Ahmed et al., 2003)
CEL – Carboxyethyl lysine
MOLD – Methylglyoxal lysine dimer
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General anatomy of the eye
The eye is a very unique organ which can sense as few as 3 photons, converts this into a signal and
pass it on to the central nervous system (Berman, 1991; Rieke & Baylor, 1998; Whikehart, 2004).
The eye is a spherical structure made of three layers- a) outer sclera, b) the middle choroid layer,
ciliary body, iris and c) the inner nervous tissue layered retina. The sclera is a tough fibrous coating
that protects the inner layers. It is white except in the transparent corneal region which allows the
light to pass into the eye. The choroid layer situated below the sclera and constitutes many blood
vessels with the iris in the front. The retina is approximately 0.5 mm thick and lines the back of
the eye. The optic nerve containing the ganglion cell axons runs to the brain and the retinal blood
vessels that open into the retina vascularize the retinal layers and neurons. The structure of each
tissue in the eye has to be intact for the proper functioning.

Figure 3– Anatomy of the eye
(Reference: http://www.biographixmedia.com/human/eye-anatomy.html)
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Photobiology of the lens
The lens is a transparent, biconvex structure in the eye that helps to refract and focus light on the
retina. The lens, by accommodation, can change the focal distance of the eye so that it can focus
on objects at various distances, thus allowing a sharp image to be conveyed to the retina. The outer
edge of the lens is made of a single layer of epithelial cells. These cells do not divide. However,
some of the cells lose their nuclei and other organelles and form lens fiber cells that are filled with
lens proteins predominantly alpha crystallin. The lens fiber cells are avascular and have no protein
turnover. As a result, chemical and light induced damage accumulates throughout the human life
span. This makes the lens an ideal model to study aging as well as diabetes.
Photo-oxidation of the lens is predominant in the epithelial cells. Damage to these cells would
readily compromise the integrity of the lens leading to the formation of a cataract (James Dillon,
1991; Eric L Finley, Mark Busman, James Dillon, Rosalie K Crouch, & Kevin L Schey, 1997;
Martin McDermott, Raul Chiesa, Joan E Roberts, & James Dillon, 1991). The primary target site
for photo-oxidation has been found to be the tryptophan residues on the crystallin proteins (Ervin,
Dillon, & Gaillard, 2001; Eric L Finley et al., 1997; Mandal, Dillon, & Gaillard, 2000; M.
McDermott, R. Chiesa, J. E. Roberts, & J. Dillon, 1991). During the aging of the lens, several posttranslational modifications occur – disulfide and non-disulfide crosslinking, glycation, protein
fragmentation (Lund, Smith, & Smith, 1996) , yellowing (James Dillon, 1991; Eric L Finley et al.,
1997; Martin McDermott et al., 1991) and non-tryptophan fluorescence (Bando, Ishii, & Nakajima,
1976; R. Kurzel, M. Wolbarsht, B. Yamanashi, G. Staton, & R. Borkman, 1973). These changes
lead to gradual decrease in solubility of the protein and the formation of aggregates.
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Cataract and Presbyopia
Cataract formation in the eye lens is the leading cause of blindness around the world affecting
about 20 million people. Development of a cataract depends on several factors such as genetics,
age, living environment and food habits. If light absorption and scattering by the lens interferes
with the vision, it indicates the formation of cataract. Cataracts may be white or yellowish brown.
Symptoms include image blurring, halos seen around headlights while driving at night, and a
decrease in the ability to see colors in the blue region of the spectrum. Due to a change in refractive
index of the lens, some people may also have a temporary improvement in vision during early
cataract formation. The most common type of cataract is age related. Cataracts can be of three
types – cortical, nuclear and posterior sub-capsular which are respectively in the anterior, center
and posterior regions of the lens (Zigman, 1977).
Reports from the literature suggest that diabetes induced non-enzymatic glycation is primarily
responsible for formation of cataracts (Caird, Hutchinson, & Pirie, 1964). Cataract has been
usually associated with damage to the structure of lens fiber cells and aggregation of the crystallin
proteins (Augusteyn & Koretz, 1987; Spector, Freund, Li, & Augusteyn, 1971). Dillon et al have
shown that aging, oxidative stress and photochemical reactions are the key factors associated with
cataract by chemically modifying the lens proteins (Ervin et al., 2001; E. L. Finley, M. Busman,
J. Dillon, R. K. Crouch, & K. L. Schey, 1997; Gaillard, Zheng, Merriam, & Dillon, 2000; M.
McDermott et al., 1991).
Change in curvature of the lens helps in adjusting the focal distance of the eye so that it can focus
of objects at different distances. This adjustment is called accommodation. Presbyopia is a
common ocular condition observed in the patients above 50 years and it is characterized by loss of
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flexibility in the crystalline eye lens and consequently, accommodation (HH von Helmholtz).
Studies show that change in physical and mechanical properties of the lens leads to gradual loss
of elasticity of the lens (Glasser & Campbell, 1999). Heys et al have shown that there is a dramatic
increase in the stiffness of the lens with age using dynamic mechanical analysis (Heys, Cram, &
Truscott, 2004). Truscott et al have suggested that heat induced damage to the lens fibers causes
the crystallin proteins to aggregate, contributing to the lens stiffness (Karl R Heys, Michael G
Friedrich, & Roger JW Truscott, 2007; Roger John Truscott, 2009; Roger JW Truscott & Zhu,
2010). Common treatments for presbyopia include magnifiers, bifocal eyeglasses, reading
eyeglasses and multifocal contact lenses that help focus at all distances.
Diabetic retinopathy and Age-related macular degeneration
In the posterior part of the eye, diabetic retinopathy (DR) is the leading cause of blindness in
Americans of working age and the third leading cause of blindness in the US (Morello, 2007).
Mismanaged diabetes leads to retinal hypoxia, which induces the Muller cells to release of a
number of vasoactive factors such as VEGF and IGF which promote angiogenesis, tissue
remodeling and consequently visual impairment (Bringmann et al., 2006; Brooks, Gu, Kaufmann,
Marcus, & Caldwell, 1998; Hirata et al., 1997; Robbins, Conaway, Ford, Roberto, & Penn, 1997;
Spilsbury, Garrett, Shen, Constable, & Rakoczy, 2000; Stone et al., 1995; J. Wang, Xu, Elliott,
Zhu, & Le, 2010).
Age-related macular degeneration (AMD), the major cause of blindness in the elderly population
in the Western World, is a multi-factorial disease that progresses from damage of the retinal
pigment epithelium. In the exudative or the wet form (10-15 % cases), abnormal angiogenesis
causes choroidal neovascularization under or above the pigment epithelium, inducing severe visual
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impairment in untreated cases (Amin, Puklin, & Frank, 1994; Campochiaro, 2000; Cohen,
Laroche, Leguen, Soubrane, & Coscas, 1996; Freund, Yannuzzi, & Sorenson, 1993; Grossniklaus
& Green, 2004; Ishibashi et al., 1997; Kwak, Okamoto, Wood, & Campochiaro, 2000; Nozaki et
al., 2006).
Ocular barriers to drug delivery
Static barriers
The cornea is a strong clear transparent anterior region that lets the light pass into the eye (Fig 4).
The adult cornea has radius of about 8 mm and covers about one-sixth of the total outer surface of
the eye ball. It is a vascular tissue to which nutrients and oxygen are supplied by the lachrymal
fluid, aqueous humor and the blood vessels that lines the junction between the cornea and sclera
(Greaves & Wilson, 1993). The cornea is the main permeation source for a drug to pass into the
eye. The cornea is made of 5 layers – epithelium, Bowman’s layer, stroma, Descemet’s membrane
and endothelium. The corneal epithelium is the main barrier to drug absorption into the eye because
of its impermeable nature. The basal cells are tightly packed in the epithelium as a defensive
mechanism to prevent entry of micro-organisms and in the process also prevents any drug
absorption. Drugs penetrate the corneal epithelium either by transcellular or paracellular pathway
as Fig 5 (Huang, Tseng, & Kenyon, 1989). Lipophilic drugs pass through the transcellular pathway
while hydrophilic drugs penetrate through the paracellular pathway (passive or altered diffusion
through intercellular spaces). Bowman’s membrane is acellular and situated between epithelium
and stroma. The stroma accounts for about 90% of the corneal thickness and has approximately
85% water and about 200-250 collagenous lamellae. These lamellae are responsible for the
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physical strength as well as optical transparency. The stroma selectively allows only the diffusion
of hydrophilic solutes (Chien, 1992).
The conjunctiva is responsible for the formation and maintenance of the pre-corneal tear film and
also in the protection of the eye. The conjunctiva is composed of an epithelium, a highly vascular
substantia propia and a submucosa. The epithelial cells are arranged in tight junctions making the
conjunctiva relatively impermeable. While the cornea only allows molecules smaller than 5000
Da, conjunctiva allows molecules up to 20000 Da to enter the eye.
The vitreous is a transparent, colorless, gelatinous mass that fills the space between the lens and
the retina lining the back of the eye. Its composition is similar to the cornea, but contains very few
cells, no blood vessels, and 98-99% of its volume is water with salts, sugars, vitrosin (type of
collagen), a network of collagen type II fibers with the glycosaminoglycan, hyaluronic acid, and a
wide array of proteins. Due to its highly hydrophilic nature, it acts as a barrier to the permeability
of hydrophobic drugs (Balazs, 1982; Los, van Luyn, & Nieuwenhuis, 1999).
The retina is a multilayered membrane of the posterior segment. A fully developed retina (Fig 6)
comprises several layers - inner limiting membrane, optic fiber layer, ganglion cell layer, inner
plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, outer limiting
membrane, photoreceptor layer, and the retinal pigment epithelium (RPE). Overall the retina can
be broadly split into 2 regions - neural retina and the RPE. While the former is actively involved
in signal transduction, the latter is responsible for supporting and maintaining the viability of the
neural retina. Together, these two regions constitute the blood retinal barrier (BRB), which plays
an important role in limiting the entry of xenobiotics and preventing the loss of essential nutrients.
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BRB disruption is mainly responsible for disturbing the function of the retina and in turn leading
to changes in vision (P. Donaldson & Lim, 2008; Tombran-Tink & Barnstable, 2008).

Figure 4– Structure of the cornea
(Reference: http://www.medicatravel.co.uk/0.2-OmMedicaTravel.htm)

Figure 5– Mechanism of transport across the static barriers
(Reference: http://www.medscape.com/viewarticle/734991_3)
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Figure 6– Illustration of the retinal structure
(Reference: http://www.jenmaggio.com/381163/medical)
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Dynamic barriers
The nasolacrimal drainage system consists of 3 parts: secretory system, distribution system and
the excretory system. The lacrimal gland constitutes the secretory system and produces tears. It is
stimulated by blinking, tear evaporation and parasympathetic stimulation due to physical or
emotional stress. The distributive system contains the eye lids and the tear film which spread tears
over the ocular surface preventing drying. The excretory part contains lachrymal puncta,
canaliculi, lachrymal sac and the nasolacrimal duct. After instillation of the drug, the lacrimal fluid
flow removes the drugs from the eye surface. Though the turnover is only about 1µL/min, excess
drug solution flows into the nasolacrimal ducts within 2 minutes. Due to frequent doses, the drug
enters the systemic circulation from the nasolacrimal glands. As a result, it increases the overall
bioavailability in the body increasing the toxicity of the drug (Chien, 1992; Huang et al., 1989;
Järvinen, Järvinen, & Urtti, 1995; Sunkara & Kompella, 2003; Urtti et al., 1990; Urtti & Salminen,
1993; Urtti, Salminen, & Miinalainen, 1985).
The barrier properties of the BRB are similar to that of the blood–brain barrier (BBB). The
intercellular spaces of the retinal endothelium are sealed with zonulae occludens, limiting the
permeability of molecules across the membrane. The retinal endothelium is also referred to as
inner blood–retinal barrier (iBRB). The endothelial cells, along with their junctional complexes,
restrict the entry of proteins as small as 20 kDa. The transport of the small molecules as well as
macromolecules is restricted from the vitreous across the retina into capillary lumen and vice versa,
showing the bidirectional effectiveness of the barrier (Cunha-Vas, 1980; J. G. Cunha-Vaz, 1976;
Jose G Cunha-Vaz, 1997; Peyman & Bok, 1972).
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Novel drug delivery systems
Conventional ocular drug delivery systems are fairly inefficient in delivering the drugs – both
small molecules and biologics to the target site owing to several physiological barriers in the eye
mentioned above. As a result, drug doses have to be given at regular intervals. Thus, novel ocular
drug delivery systems are being studied to overcome problems like improving ocular contact time,
enhancing site specificity and also increasing corneal permeability. Some of the NDDS which are
under research or in market are as follows:
Polymers
Addition of polymers as excipients into aqueous vehicles was employed as a means to increase the
ocular contact time of drug (Le Bourlais et al., 1998). Increased viscosity of the solution reduces
the washing away of the drug by tears. However, this approach is not applicable to hydrophobic
drugs. Therefore, increasing solution viscosity by incorporating synthetic polymers like polyvinyl
alcohol, polyvinyl pyrrolidone and cellulose derivatives has very limited utility.
Mucoadhesives
External surface of the sclera is coated with the thin film of glycoprotein called as mucin. The
mucin layer forms the tear film which nourishes, lubricates and protects the corneal epithelium,
conjunctiva epithelium & cul-de-sac. Mucoadhesive polymers help in prolonging the release of
the drug from a dosage form by localizing it at a specific site where the mucus is present. They
remain in contact with the precorneal tissues until mucin turnover causes elimination of the
polymer. Best mucoadhesive polymers are selected based on the charge density, number of polar
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groups for hydrogen bonding & hydrophilic-lipophilic balance (HLB) in the polymer chain (Asija,
2013;Greaves & Wilson, 1993; Kashikar, 2011; Ludwig, 2005). A list of natural & synthetic
mucoadhesive polymers that can be used for ocular drug delivery are listed in Table 1.

Table 1– List of viscosifying polymers
(Thakur & Kashiv, 2011)
POLYMER USED TO TREAT DRY EYE

ADHESIVE PERFORMANCE

Carboxy methyl cellulose

Excellent

Carbopol

Excellent

Hydroxypropylmethyl cellulose

Good

Polyacrylamide

Good

Polycarbophil

Excellent

Gelatin

Fair

Dextran

Good

Hyaluronic acid

Excellent

Ophthalmic inserts
These are polymer based delivery devices for placement into the cul-de-sac. It offers an attractive
approach to the problem of extending the residence time of the drug on the corneal surface. The
ophthalmic inserts are of 2 types: 1) non-erodible inserts and 2) erodible inserts
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1) Non-erodible Inserts:
i) Ocusert. It is currently available in the market for the treatment of chronic glaucoma. It is an
elliptical device consisting of three layers containing the drug reservoir. It is preprogrammed to
release pilocarpine, an anti-glaucoma drug at a constant rate of 20- 40 µg/hr (Stewart & Novak,
1978).
ii) Contact lenses (Brand – PureVision). Therapeutic soft lenses are often used as bandage lenses
for corneal protection and pain relief in patients with marked thinning of cornea (Hayworth &
Asbell, 1990). The drug is incorporated into the contact lens by presoaking the lens in the drug
solution. However, the drug releases from the lenses within 30 min, thereby, cannot be used for
prolonged drug delivery. Oxygen supply to the eye, buildup of harmful metabolite such as CO2
and infections are some of the complications that arise due to the use of presoaked contact lens
(Cheng et al., 1999). An alternative approach has been developed to incorporate the drug into a
monomer matrix. The polymerization is then carried out to produce the contact lens. With this
approach, the release of the small molecule drug is significantly prolonged to many hours
compared to presoaked lenses. (Ambroziak, Szaflik, & Szaflik, 2004; Christie, 1999; de Oliveira
& Bailey, 2004; Gould, 1970; Hayworth & Asbell, 1990; Lim, Tan, & Chan, 2001; Plotnik,
Mannis, & Schwab, 1991; Rosenthal, 2012; Smiddy, Hamburg, Kracher, Gottsch, & Stark, 1990;
Weed, 1996).
iii) Ocufit. It is a sustained-release, rod-shaped device made of silicon elastomer. It was designed
to fit the shape and size of the human conjunctival fornix. The insoluble Ocufit has been
reported to have two advantages - long retention time and sustained drug release (Khan, Warchol,
& Romberg, 1996; Weiner, Darougar, Siddiqui, & Raul, 1993).
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2) Erodible Inserts:
i) Lacrisert. It is a sterile device made of hydroxypropyl cellulose for the treatment of dry eye
syndrome. It imbibes water from the conjunctiva & cornea, forms a hydrophilic film to stabilize
the tear film, hydrate and lubricate the cornea (Khan et al., 1996; Weiner et al., 1993; Yasukawa
& Ogura, 2010).
ii) SODI. Soluble Ophthalmic Drug Insert (SODI) is a small oval wafer made from acrylamide,
N-vinyl pyrrolidone & ethyl acrylate (ratio 0.25: 0.25: 0.5). When placed in the inferior cul-desac, it is wetted by the tear film, and turns into a viscous polymer mass. Daily application of SODI
is used for the treatment of glaucoma (Bloomfield et al., 1978; Gurtler, Kaltsatos, Boisramé, &
Gurny, 1995; Le Bourlais et al., 1998; Mundada & Shrikhande, 2006).
iii) Minidisc: The major component of the minidisc is a silicone based pre-polymer -α-ω-bis(4methacyloxy)-butyl polydimethylsiloxane (M2DX). It can either be hydrophilic or hydrophobic to
permit the release of both water soluble & insoluble drugs (Mansouri & Shaarawy, 2011).
Nanoparticles:
Nanoparticles can be used to solve various solubility-related problems of poorly soluble drugs,
like dexamethasone, budenoside, gancyclovir. Depending on the physicochemical properties of
the materials, nanoparticles can be designed to overcome retinal barriers. Biodegradable polymers
like chitosan nanoparticles, polyamidoamine (PAMAM) dendrimers, poly (lactic-co-glycolic) acid
(PLGA) nanoparticles are being investigated to treat inflammation (Bourges et al., 2003; Hans &
Lowman, 2002; Kompella & Edelhauser, 2011; Nagarwal, Kant, Singh, Maiti, & Pandit, 2009;
Rowe-Rendleman et al., 2014; Sahoo, Dilnawaz, & Krishnakumar, 2008; Soppimath, Aminabhavi,
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Kulkarni, & Rudzinski, 2001; Zimmer & Kreuter, 1995). Merodio et al showed that albumin
nanoparticles have been successful in sustaining the release of Ganciclovir for the treatment of
cytomegalovirus retinitis (Merodio, Arnedo, Renedo, & Irache, 2001; Merodio, Socorro Espuelas,
Mirshahi, Arnedo, & Irache, 2002). Kang et al prepared PAMAM dendrimers of carboplatin and
administered them into the subconjunctival space of a murine model for retinoblastoma and
obtained a sustained release of drug over 22 days. However, these nanoparticles do not have a
huge payload and hence cannot be used for more prolonged drug delivery.
Liposomes:
Liposomes are concentric vesicles composed of lipid membrane enclosing an aqueous volume.
They can be compartmentalized to deliver both hydrophilic & hydrophobic drugs. Ocular delivery
via liposomes is significant for lipophilic drugs to a greater extent than hydrophilic drugs.
Positively charged liposomes seem to be preferentially captured at the negatively charged corneal
surface, thereby, increase the corneal absorption time (Gad, 2008). Abrishami et al have been able
to obtain a sustained release of the anti-VEGF drugs up to a period of 42 days (Abrishami et al.,
2009). Liposomes are potentially useful systems for ocular delivery but they are not very popular
because of their short shelf life, limited drug capacity, and problems in sterilization (Bochot &
Fattal, 2012; Ripal Gaudana, Ananthula, Parenky, & Mitra, 2010; Hathout, Mansour, Mortada, &
Guinedi, 2007; Hironaka et al., 2009; Honda et al., 2013; Hosny, 2010; Jafari, Jones, Hikal,
Williamson, & Wyandt, 1998; Jain & Shastri, 2011; Lajunen et al., 2014; Lichtenberg &
Barenholz, 1988; Mehanna, Elmaradny, & Samaha, 2010; Sultana, Maurya, Iqbal, & Aqil, 2011).
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Photochemistry of fluorescence
When a molecule absorbs a photon, an electronically excited state is formed which induces
structural changes. The absorbed energy from light leads to photochemical changes in the
absorbing molecule, or its microenvironment. The energy can also be released as heat, or in the
form of light for the molecule to return to its ground state. Based on the structure of the molecule,
there are different mechanisms for the molecule to dissipate the excess absorbed photon energy.
This can be explained using a Jablonski Diagram as shown in Fig 7.
Excited states may be classified as singlet or triplet based on their electron spin angular
momentum. The electrons in most non-metallic organic compounds are paired (opposite spins) in
bonding and non-bonding orbitals, resulting in a net zero spin diamagnetic molecule for the ground
state (Turro, 1991). A singlet state is one in which all of the electrons in the molecule have their
spins paired. Triplet states are those in which one set of electron spins have become unpaired. The
distinction between singlet and triplet states is important because photon induced excitation always
leads to a state of the same multiplicity, i.e. singlet to singlet or triplet to triplet (Valeur &
Berberan-Santos, 2012).
Internal conversion of excited states to lower energy states of the same multiplicity takes place
rapidly with loss of heat energy (non-radiative relaxation). Alternatively, an excited state may
return to the ground state by emitting a photon (radiative decay). Nearly 80% of the excited singlet
states lose energy by internal conversion and about 3% by fluorescence (Lakowicz, 2007).
Conversion of a singlet state to a lower energy triplet state, or vice versa, is termed intersystem
crossing and is slower than internal conversion. Radiative decay from a triplet state is called
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phosphorescence and is generally quite slow. The approximate timescales for the transitions that
occur in one bond vibration are given in Table 2.

Table 2 - Approximate time scales of different electronic state transitions in one bond vibration
(www2.chemistry.msu.edu/faculty/reusch/virttxtjml/photchem.htm)

Process

Transition

Time scale (sec)

Light Absorption (Excitation)

S0 → Sn

10-15 (instantaneous)

Internal Conversion

Sn → S1

10-14 to 10-11

Vibrational Relaxation

Sn* → Sn

10-12 to 10-10

Intersystem Crossing

S1 → T1

10-11 to 10-6

Fluorescence

S1 → S0

10-9 to 10-6

Phosphorescence

T1 → S0

10-3 to 100

Non-Radiative Decay

S1→S0

10-7 to 10-5

T1 → S0

10-3 to 100

where: S = singlet state and T = triplet state
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Figure 7– Jablonski Diagram
(http://www.ibs.fr/groupes/groupe-dynamique-et-cinetique-des/pixel/photophysique-desproteines/?lang=fr
Time resolved fluorescence – measurement of fluorescence lifetimes
The fluorescence lifetime is a measure of the time a fluorophore spends in the excited state before
returning to the ground state by emitting a photon (Hercules, 1966). If a population of fluorophores
is excited, the lifetime is the time it takes for the number of excited molecules to decay to 1/e or
36.8% of the original population according to:
[A] = e-kt
[A]O
when, [A] = 1/e *[A]O ; t = Ʈ
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As shown in the intensity decay Fig. 8, the fluorescence lifetime, Ʈ, is the time at which the intensity
has decayed to 1/e of the original value. The decay of the intensity as a function of time is given
by:
It = α e-t/τ
Where It is the intensity at time t, α is a normalization term (the pre-exponential factor) and τ is
the lifetime.
Knowledge of the excited state lifetime of a fluorophore is crucial for quantitative interpretations
of numerous fluorescence measurements such as quenching, polarization and FRET. Excited state
lifetimes have traditionally been measured using the “time domain” method or the “frequency
domain” method (Lakowicz, 2007). In the time domain method, the sample is illuminated with a
short pulse of light and the intensity of the emission versus time is recorded. Originally, these short
light pulses were generated using flash lamps that had widths on the order of several nanoseconds.
Modern laser sources can now routinely generate pulses with widths on the order of picoseconds
or shorter.
The time-domain method is a direct technique to measure fluorescence decay curves (i.e.
fluorescence intensity v/s time). From the change in fluorescence intensity with time, we can
determine the lifetimes by examining raw decay data and a proper fitting function. In order to
obtain the fluorescence lifetime, the profile of excitation pulse (instrument response function) has
to be measured in addition to the fluorescence decay as shown in Fig 8.
Instrument response function (IRF) is the reference decay obtained from the instrument using a
known scattering solution. The fluorescence decay from the sample is compared to the IRF using
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a proper fitting analysis with deconvolution (Fig. 9). This analysis generates the lifetime values as
well as the relative contributions to total fluorescence at time zero (Lakowicz, 2007; Mandal et al.,
2000). The data fit can be evaluated based on the χ2 value, Durbin-Watson parameters,
autocorrelation function and the random distribution of the weighted residuals.

Figure 8– Fluorescence decay curve
(http://www.iss.com/resources/research/technical_notes/K2CH_FLT.html)
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Figure 9- Experimental laser profile and decay (dotted functions) and the best numerical fit in a
typical time-domain experiment. The true exponential function represents the model decay, i.e. a
hypothetical decay if the laser pulse was infinitely narrow.
(http://www.pti-nj.com/TechnicalNotes)
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CHAPTER 2 - MATERIALS AND METHODS
Materials
Glycolaldehyde, glucose, sucrose, trizma base, sodium phosphate, potassium phosphate, mannitol,
trehalose and high-performance liquid chromatography (HPLC) grade Methanol (MeOH) were
purchased from Thermo Fisher Scientific (Pittsburgh, PA, USA). Sodium chloride, disodium
fluorescein, methylglyoxal, aniline naphthalene sulfonic acid (ANS), urea, ammonium
bicarbonate, dithiothreitol (DTT), iodoacetamide (IAA), human serum albumin, cholesterol,
rhodamine 6G, bromophenol blue, sodium dodecyl sulfate (SDS), beta-carotene, canthaxanthin,
phosphatidylcholine and 5,6-carboxyfluorescein succinimidyl ester were from Sigma-Aldrich (St.
Louis, MO, USA). Sequence grade trypsin and chymotrypsin were purchased from Promega
(Madison, WI, USA). High quality phospholipids used for preparing liposomes like 1,2dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine (DPPE), 1,2-distearoyl-sn-glycero-3- phosphoethanolamine (DSPE), 1,2dioleoyl-sn-glycero-3-phosphoethanolamine

(DOPE),

1,2-dipalmitoyl-sn-glycero-3-

phosphoethanolamine-N-[methoxy(polyethylene

glycol)-2000]

(ammonium

salt)

(DSPE-

PEG2000) and 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) (DPPG)
were purchased from Avanti Polar lipids, Inc. Milli-Q-water was produced via Millipore Milli-Q
Plus Purepak 2 water purification system (EMD Millipore, Bellerica, MA).
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Methods
Extraction of Lenses
Fresh bovine eyes were obtained from Aurora Packing Company (Aurora, IL) and calf lenses were
obtained from Brown Packing Co. (South Holland, IL). These tissues were all excised and from
animals that were less than 30 months old. The tissues were obtained 4–5 hr after slaughter and
stored at 4 °C for up to 10 hrs. Whole human donor lenses were obtained from the Chicago Eye
Bank within 2 days after death. The lenses from donor age range of 6 - 90 years were used for this
study. Each lens was isolated by making a scleral incision to remove the compartments of the
anterior segment and cutting the vitreous gel. The lenses were stored at -70oC in the dark till the
day of use.
Extraction of Bovine Alpha Crystallin
Fresh bovine lenses were weighed and then homogenized by stirring in a buffer prepared using 50
mM Tris/0.2 M NaCl/1 mM EDTA/10 mM mercaptoethanol, pH 7.4 at 4oC. The supernatant was
centrifuged at 14000 g for 1 hr. at 4oC. Alpha-crystallin was isolated from the total soluble lens
protein solution by size exclusion chromatography. A total of 30 ml supernatant was loaded on a
1.7cm x 100 cm CL-6B sepharose gel filtration column, and using a peristaltic pump, eluted at a
flow rate of 1 ml/min and monitored by absorbance at 280 nm. Alpha crystallin elutes first as a
single symmetrical peak at approximately 170 ml of the buffer corresponding to an apparent
molecular mass of 800 KDa. The isolated α crystallin fractions were pooled and desalted with
Ultrafree-15 Biomax-10K centrifugal filter devices (Millipore Corporation, Bedford, MA) at a
speed of 3000 rpm by rinsing three times with water. The purity of the sample was determined by
SDS-PAGE with the Pharmacia LKB*Phast System.
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UV- Visible spectrophotometry
The absorbance from α-crystallin fractions collected after size exclusion chromatography was
measured using Perkin Elmer UV-Vis Spectrophotometer.
SDS-PAGE electrophoresis
Pharmacia LKB*Phast System was used for this experiment. 100 ml of 10 mϺ of Tris/HCl buffer
with 1 mϺ EDTA, pH 8.0, 10 ml of 10% SDS, β-mercaptoethanol, 10 ml of 0.2% bromophenol
blue, 200 ml of Coomassie Blue staining solution, 600 ml of destaining solution and 200 ml of
preserving solution were prepared according to the protocol.
0.5 mg of Alpha crystallin was dissolved in 5 ml of buffer containing 10 mϺ Tris/HCl, 1 mϺ
EDTA, pH 8. To 65 µl of the protein solution, 25 µl of 10% SDS and 5 µl of β-mercaptoethanol
were added. This mixture was heated at 100oC for 5 minutes. Then, the sample was cooled and 5
µl of bromophenol blue was added. The gel compartment of the Phast gel system was prepared by
cleaning with MQ water. The gel was positioned and the sample was applied using an applicator.
The sample was run for 30 min; then the gel was subjected to staining using the Coomassie blue
staining solution for about 45 min. Excess stain from the gel is removed by using the destaining
solution to reveal the bands.
Tryptic digestion for mass spectrometry
Enzymatic digests were performed on the α-crystallin samples. Each protein was prepared to have
a concentration of 1mg/mL in water. A solution of 8 M urea and 0.4 M ammonium bicarbonate
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(pH 7.5- 8.5) was prepared as the digestion buffer. An aliquot of 150 μL of the protein solution
was added to 200 μL of the urea and ammonium bicarbonate solution. A 50 μL sample of 50 mM
dithiothreitol was added to the sample and then allowed to incubate at 50 ºC for 15 min. After
cooling to room temperature, a 50 μL sample of 100 mM iodoacetamide was added to the protein
sample and left to react in the dark for 15 mins. The sample was then diluted by adding 350 μL of
MQ water. The Promega sequencing grade trypsin was suspended in 200 μL of 50 mM acetic acid
and a 25 μL aliquot was removed and added to the diluted protein sample. The sample was then
allowed to incubate at 37ºC overnight or up to a total of 24 hrs.
Non-enzymatic glycation of alpha crystallin
a) Model for studying the biophysical changes1M Glucose, 1M Sucrose and 0.05 M Glycolaldehyde (GA) stock solutions were added to alpha
crystallin to obtain a final concentration of 10 mM in 1 mg/ml dilute alpha crystallin solution. The
samples were incubated at 25oC in the absence of light for 0-5 weeks. Another glycating agent,
Methyl glyoxal (MGO) was used at a concentration of 10 μM in 1mg/ml alpha crystallin solution
and incubated at 25oC for 0, 0.5,1,3,6 and 9 hr respectively. All the solutions were dialyzed against
10 mM phosphate buffer, pH 7.4 before the measurements, lyophilized and reconstituted with 1
ml of MQ water. These reconstituted samples were used to measure the change in particle size
using dynamic light scattering.
b) Model for studying the fluorescent biomarkersBovine alpha crystallin was used as the model protein to study the progression of glycation. Methyl
glyoxal (MGO) was used as the glycating agent at a concentration of 2.5 μM in 1mg/ml alpha
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crystallin solution and incubated at 37oC over a period of 60 days. The aliquots were collected
every 10 days; dialyzed against 10 mM phosphate buffer, pH 7.4. These samples were lyophilized
until further analysis.
Non-enzymatic glycation of intact lenses using glucose
Pig lenses were used as a model for in vitro non-enzymatic glycation under controlled conditions.
The lenses were weighed immediately after extraction from the eye balls and then incubated in 1M
glucose solution in 10 mM phosphate buffer with 0.1% sodium azide for a period of 2 months at
37oC. The samples were cleaned using MQ water and then frozen in -70oC until future use.
Dynamic Light scattering measurements
The particle size was measured by Dynamic light scattering (DLS) on a Brookhaven BI-200SM
Research Goniometer and Laser Light Scattering System (5mW He–Ne laser, λ=632 nm) using
CONTIN software. To obtain the diffusion coefficient, the intensity correlation function must be
analyzed. The hydrodynamic diameter and the particle size distribution were generated by the
software. The temperature was fixed at 20°C. Accuracy of the data was determined based on
polydispersity and baseline difference from the correlation curve. From the mean hydrodynamic
diameter, the translational diffusion co-efficient (DT) was calculated using Stokes- Einstein
equation:
DT = kT/ (6πηRH)
where: k= Boltzmann constant (1.38 ×10−23 J/K), T = temperature (300 K), η = viscosity of the
medium, RH = Hydrodynamic diameter

31

Static Light Scattering measurements
The intensity of the scattered light depends on the polarizability, which in turn depends on the
molecular weight. This property of light scattering makes it a valuable tool for measuring
molecular weight. The light scattering intensity depends on scattering angle. The maximum
scattering intensity is at Ɵ = 0. The minimum scattering intensity is at Ɵ = 90. The scattering
intensity for forward scattering is equal to the intensity for back scattering at the corresponding
angle.

where:

Scattering vector for vertically polarized light,

In the above equations,
n0 - Refractive index of the solvent,
λ - Wavelength of the light source (633 nm)
NA - Avogadro number (6.023x1023)
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c - Solution concentration
dn/dc - Change in refractive index of the solution with change in concentration.
The intensity of the analyte measured at an angle is IA(θ). In these equations, the subscript A is for
analyte solution and T is for the toluene with the Rayleigh Ratio of toluene, R T being 1.35x10−5
cm−1 for a HeNe laser.
Approximate molecular masses of modified and unmodified alpha crystallin samples were
determined using Static Light Scattering (SLS). A Zimm plot was constructed from the light
scattering intensities obtained at multiple angles (10, 20, 30, 40, 50, 60, 70, 80, 95, 100, 110 and
120) and different concentrations (0.1, 0.25, 0.5 and 1 mg/ml). Next, the intercepts of the first plots
are plotted as a function of concentration. The resulting plot should be a straight line with

The slope and intercept of the second line gives us Molecular weight and the second virial
coefficient.
Surface hydrophobicity measurements
The surface hydrophobicity of the native and MGO modified alpha crystallin was studied using a
specific hydrophobic probe, 1-anilinonaphthalene-8-sulfonic acid (ANS). Ten microliters of a 10
mM methanolic solution of ANS was added to 1 mL of protein [0.1 mg/mL in 10 mM phosphate
buffer (pH 7.4)], and the mixture was incubated for 1 hr in the dark at 25°C. Fluorescence emission
spectra were recorded between 400 and 600 nm using an excitation wavelength of 370 nm. The
excitation and emission band-passes were 5 nm each.
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Secondary structure determination using Circular Dichroism
Secondary structure analysis was performed by far UV CD using Aviv Circular Dichroism
Spectrometer, model 215 with a 50 KHz photoelastic modulator. The spectra were recorded with
0.01 cm path length quartz cuvette between 200 and 250 nm using a slit width of 1nm and a scan
speed of 20 nm/min.
Refractometry
Abbe's refractometer was used to measure the refractive index of the given liquid. Using a sodium
lamp light source, the apparatus was calibrated with water as the liquid. The micrometer screw
was adjusted to focus the boundary between the bright and dark regions. The refractometer scale
was adjusted to place the cross wire of the telescope exactly on the boundary between the bright
and dark regions. The same process was repeated for unmodified and modified alpha crystallin
solutions after the equipment was calibrated.
Small Angle X-ray Scattering measurements
Concentrated samples of alpha crystallin and glycated alpha crystallin have been studied using
SAXS. These studies were performed at the 8-ID-I beam line of the Advanced Photon Source at
Argonne National labs, IL. The sample in a sealed capillary was placed in the beam line under
vacuum. Coherent X ray photons of energy 7.35 keV were focused using a Kinoform lens placed
upstream of the sample. The scattered photons were detected by a PI LCX-1300 direct detection
CCD (Princeton Instruments, USA) 4.0 m downstream of the sample. A single camera width spans
about 0.3 nm-1 in the scattering vector (Q) space. The intensities were measured at 6 overlapping
camera widths covering a Q range from 0.1- 1 nm-1. For a given camera position, 20 frames were
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collected with an exposure time of 0.2 s for each frame. The shorter exposures of 0.2 s and moving
the beam spot to a different location and camera to a new position helps to minimize the radiation
damage caused by the X-ray beam. The resulting image pixels were analyzed by a MATLAB GUI
to obtain the time averaged intensity profiles as a function of the scattering vector. The interparticle distance between the sub-units can be determined from scattering vector Q using Qmax =
2π/d; where d = distance between adjacent sub-units.
Steady state fluorescence measurements
a) For glycation experiments:
The advanced glycation endproduct (AGE) fluorescence of unmodified and methyl glyoxal
modified α-crystallin was measured using Hitachi F2500 Fluorescence Spectrometer. The
fluorescence emission spectrum of the samples was recorded between 400-700 nm using 340, 370,
400, 435, 460 and 488 nm as excitation wavelengths maintaining the slit widths at 5 nm and PMT
voltage of 400V. The same procedure was repeated using the whole donor lenses to study the
spectral properties of the fluorophores.
b) For liposomal drug release studies:
Fluorescence intensity of the markers encapsulated in the liposomes was measured by excitation
at 488 nm and screening the emission from 500 -700 nm by maintaining the slit widths at 5 nm
and PMT voltage of 400V.
Time-resolved fluorescence measurements
The lifetime profiles for the fluorescence decay of fluorophores in unmodified and modified alpha
crystallin (10 mM phosphate buffer at pH 7.4) were measured by using TimeMaster™ LED system
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(TM-2000). The samples were excited in UV-A region at 340, 370 nm and in visible region at 435,
488 nm using a LED light source having approximately 1.5 ns pulse width. The time domain
system was used to measure the decay in fluorescence with respect to time. The raw decay data
was analyzed using global 1 to 4 three exponential fitting analysis with deconvolution which gives
the lifetimes as well as the relative contributions to the total fluorescence at time zero. These data
were assessed with a good auto correlation function around zero, weighted number of residuals
randomly distributed between +3 and -3, reduced Ӽ2 values between 0.9 to 1.1 and the DurbinWatson parameters of greater than or equal to 1.6, 1.7 and 1.8 for one, two and three exponential
decays respectively. Once the lifetimes were obtained using the model protein, the procedure was
extended to measure the fluorescence lifetimes of the intact lenses of diabetic and non-diabetic
donors. The donor lenses were positioned parallel to excitation source and the emission was
detected at right angles to the excitation beam.
Fluorescent tagging of protein
For easy detection of the model protein marker encapsulated within the liposomes, the proteins
were labelled with fluorescein. Human serum albumin and immunoglobulin G were tagged using
NHS fluorescein (5,6-carboxyfluorescein succinimidyl ester). The protein (1 mg/ml) was
dissolved in 20 mM sodium phosphate buffer with 0.15 M NaCl at pH 8.5. 4.7 µL of 15 mmol
NHS-fluorescein solution in DMSO was added to the protein solution and incubated at room
temperature for 2 hr. Unreacted NHS-fluorescein was removed by dialysis using tris-glycine buffer
at pH 8. The non-reacted dye must be completely removed for optimal results and accurate
determination of the fluorophore-to-protein ratio. The absorbance of the labeled protein at 280 nm
and 488 nm was measured to calculate the protein concentration and degree of labeling.
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a) Calculate the protein concentration:
Protein molar extinction coefficient of IgG is ~210,000 M-1 cm-1 and human serum albumin is ~
43,824 M-1 cm-1
Correction factor = A280/A488
Protein concentration (M) = A280 – (A488 x Correction factor) x dilution factor
Ɛprotein
b) Calculate the degree of labeling:
Ɛfluor = 70,000 M-1 cm-1 (NHS-Fluorescein molar extinction coefficient)
Moles fluor per mole protein = A488 of the labeled protein x dilution factor
Ɛfluor x protein concentration (M)
Preparation of liposomes by lipid hydration and extrusion method
The model dye was mixed with different combinations of phospholipids and cholesterol to obtain
a total lipid concentrations of 10 mM in chloroform- methanol mixture in solvent ratio of 2:1. The
mixture was dried on a rotary evaporator to obtain a thin film on the surface of the round bottom
flask. The film was further flushed with argon for complete drying. The lipid film was then
hydrated with phosphate buffer overnight. LIPEX 10 ml extruder was used for the extrusion. The
extruder was assembled according to the operating manual using 0.2 and 0.1 μm polycarbonate
filters. Then, the extruder assembly was coupled to a nitrogen gas line. By maintaining the pressure
between 200-300 psi, the sample was filtered 8-10 times. The final solution was lyophilized for
storage until further use.
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Preparation of liposomes by reverse phase evaporation method
Different combinations of phospholipids and cholesterol were dissolved in 2:1 chloroformmethanol mixture. The solvents were evaporated off using a rotary evaporator under vacuum at
40oC. The lipid film was re-dissolved in ether to produce reverse phase vesicles. 20 mg of the dye
was dissolved in acetone and 6 ml of PBS (pH 7.4). The system was sonicated for 4 min in a bath
sonicator. The organic phase was then evaporated using a rotary evaporator. The liposomes were
allowed to equilibrate at room temperature and then 10 ml PBS was added to liposome suspension,
which was refrigerated overnight. The final solution was lyophilized for storage until further use.
Liposomes prepared by sonication method
Different compositions of phospholipids and cholesterol were dissolved in chloroform in a glass
test tube. The phospholipid mixture was dried under N2 or Argon. Then, it is further dried under
vacuum for an additional hr. To this film, 2.6 ml of HEPES buffer saline containing dye was added
at room temperature. The dispersion was left to hydrate for 1 hr and vortexed to resuspend the
pellet to get a milky suspension. The liposome solution was sonicated to get a clear solution. The
final solution was lyophilized for storage until further use.
Preparation of liposomes by Freeze thaw method
Phospholipids and cholesterol were mixed at various molar ratios in a round bottom flask. To this,
2 ml of chloroform was added to make a uniform organic phase. The solvent was argon dried to
get a uniform film of lipid layer. This lipid layer was hydrated using the drug solution in 0.32 M
mannitol to get a final phospholipid concentration of 10 mg/ml. The dispersion was sonicated for
5 min in a bath sonicator. The solution was then frozen at -70oC for 30 min and then thawed to
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40oC. The process was repeated at least 6-7 times and the final sample was lyophilized after
removal of excess dye using the method described below.
Preparation of liposomes by modified method
Different phospholipids and cholesterol were mixed at various molar ratios in a round bottom flask.
To this, 10 ml of 2:1 ratio of methanol- chloroform mixture containing 10 µM anti-oxidant was
added to make a uniform organic phase. The solvent was removed by rotary evaporator to get a
uniform film of lipid layer. This lipid layer was hydrated using the drug solution in 0.32 M
mannitol to get a final phospholipid concentration of 10 mg/ml. The dispersion was sonicated for
5 min in a bath sonicator. The liposome solution was extruded around 10 times to obtain a uniform
particle size of around 200 nm. The solution was then frozen at -70oC for 30 min and then thawed
to 40oC for 20 min. The process was repeated at least 9-10 times and the final sample was
lyophilized after removal of excess drug.
Preparation of liposomes containing anti-oxidants by modified method
Different phospholipids and cholesterol were mixed at various molar ratios in a round bottom flask.
To this, 10 ml of 2:1 ratio of methanol- chloroform mixture containing anti-oxidants like betacarotene or canthaxanthin were added to make a uniform organic phase. The solvent was removed
by rotary evaporator to get a uniform film of lipid layer. This lipid layer was hydrated using the
drug solution in 0.32 M mannitol to get a final phospholipid concentration of 10 mg/ml. The
dispersion was sonicated for 5 min in a bath sonicator. The liposome solution was extruded around
10 times to obtain a uniform particle size of around 100-200 nm. The solution was then frozen at
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-70oC for 30 min and then thawed to 40oC for 20 min. The process was repeated at least 9-10 times
and the final sample was lyophilized.
Separation of free drug
Free unentrapped drug was separated from the liposomes by centrifugation at 17000 rpm for 1 hr
at 4oC. The pellets formed were washed with distilled water twice and then re-suspended,
centrifuged again for 1 hr. The supernatant containing unentrapped marker (Fluorescein) was
discarded.
Table 3 – Composition of various formulations in the formulation development
Formulation

Molar ratios
PC

DSPE

PS

DMPE-

DPPG

Chol

PEG 2000

Other
excipients

1

70

-

-

-

-

30

-

2

69

8

-

-

8

15

-

3

65

5

-

-

5

25

-

4

60

5

-

-

5

30

-

5

60

10

-

-

-

30

-

6

60

-

-

-

10

30

-

7

55

10

-

-

10

30

-

8

50

-

-

-

-

50

-

9

40

-

-

-

-

60

-

10

46.7

-

-

-

20

33.3

-

40

11

33.4

-

-

-

33.3

33.3

-

12

-

-

-

-

66.7

33.3

-

13

46.7

-

-

-

20

33.3

BC

14

33.4

-

-

-

33.3

33.3

BC

15

-

-

-

-

66.7

33.3

BC

16

46.7

-

-

-

20

33.3

CX

17

33.4

-

-

-

33.3

33.3

CX

18

-

-

-

-

66.7

33.3

CX

19

80

-

20

-

-

-

-

20

70

10

20

-

-

-

-

21

60

20

20

-

-

-

-

22

50

30

20

-

-

-

-

23

40

40

20

-

-

-

-

24

69

-

-

8

8

15

-

25

65

-

-

5

5

25

-

26

60

-

-

5

5

30

-

27

60

-

-

10

-

30

-

28

55

-

-

10

10

30

-

Encapsulation efficiency
The change in fluorescence signal can be used to assess the membrane permeability. Interactions
of certain solutes such as some drugs or antimicrobial peptides could reduce the stability and/or
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change the permeability of the bilayer membrane. The extent of the leakage from an encapsulated
liposome due to contact with a certain solute was determined from the relative fluorescence (%F)
of the leaked marker (fluorescein) and is calculated by equation:

where:
Ft – Fluorescence of liposomes after incubation with solute
F0 – Initial fluorescence due to dilution in an isomolar buffer
F ͚ – Maximal fluorescence after lysis by Triton X-100
For every study, the sample volume, dilution factors and the instrument parameters were kept
constant to avoid false results. The fluorescence intensity was measured at an excitation
wavelength of 488 nm and the emission was screened between 500-700 nm by maintaining the slit
widths at 5 nm and PMT voltage of 400V.
Transmission electron microscopy for imaging
Briefly, a drop of a water-diluted suspension of the liposomes (about 0.05 mg/mL) was placed on
a 200-mesh Formvar copper grid (Electron Microscopy Sciences), allowed to adsorb and the
surplus was removed by filter paper. A drop of 2% (w/v) aqueous solution of uranyl acetate was
added and left in contact with the sample for 5 minutes. The surplus water was removed and the
sample was dried at room temperature before the vesicles were imaged with a TEM operating at
an acceleration voltage of 200 KV
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Coating liposomes on the surface of IOLs
The primary coating solution was prepared by mixing appropriate pre-evaluated amounts of Polylactide glycolic acid (PLGA) in volatile solvent. The PLGA solution with rhodamine dye was spin
coated at 4000 rpm on plasma treated intraocular lenses. The lyophilized liposomes encapsulating
fluorescein were mixed into a hydrophilic coating solution (0.5 mg/ml hyaluronic acid in water,
10 mg/ml hydroxyl propyl methyl cellulose in water and 2 mg/ml methyl cellulose in water) and
coated on the top of PLGA smeared IOLs and vacuum dried for 24 hr. The final products are stored
in a sealed container and stored in the dark till further use.
Confocal Laser Scanning microscopy (CLSM) for imaging the coatings
CLSM analysis was performed with a Zeiss LSM 5 Pascal Confocal Laser Scanning Microscope
equipped with Argon (458, 488, and 514 nm) laser. In order to characterize and select the ideal
composition for the coatings, rhodamine was mixed with the PLGA coating and fluorescein
encapsulated liposomes in hydrophilic coating material were used for secondary coating.
Topography of the lens was constructed based on the fluorescence intensity measurements using
a dual scanning system.
SOTAX USP 4 apparatus for drug release studies
Drug release studies were performed using USP 4 dissolution apparatus (SOTAX Corporation).
The flow rate was maintained at 0.5 ml/min. Aliquots were removed at regular intervals and the
concentration of the drug released was screened using fluorescence spectrophotometry.
Concentration of fluorescein dye released was measured using UV-Vis spectrophotometry
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assuming the Ɛ of fluorescein to be ~76,900 M-1 cm-1. The concentration of protein in the solution
was measured based on the absorbance from the fluorescent label using the equation:
Protein concentration (M) = A280 – (A488 x Correction factor) x dilution factor
Ɛprotein
where:
Ɛ of IgG is ~210,000 M-1 cm-1
Ɛ of human serum albumin is ~ 43,824 M-1 cm-1
Correction factor = A280/A488
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CHAPTER 3- NON-ENZYMATIC GLYCATION OF α-CRYSTALLIN AS AN IN VITRO
MODEL FOR AGING AND DIABETES IN LENS
Introduction
The human eye lens is a transparent, biconvex structure that helps to refract light to be focused on
the retinal surface. The change in curvature helps in adjusting the focal distance of the eye so that
it can focus on objects at different distances. This adjustment of the lens is called accommodation.
Presbyopia is a common ocular condition observed in patients above 50 years and is characterized
by loss of flexibility of the crystalline eye lens and in turn, accommodation (Strenk, Strenk, &
Koretz, 2005; Hermann von Helmholtz, 1962, 2005). Cataract is the leading cause of blindness,
affecting 40 million people worldwide (Congdon, Friedman, & Lietman, 2003; Isaacs, Ram, &
Apple, 2004). It is a multifactorial ocular disease caused by genetics, age, and environment. There
are reports in the literature that glycation gradually damages the lens by causing aggregation of the
lens proteins (Meredith, 2006; Monnier, Stevens, & Cerami, 1979; Nagaraj & Monnier, 1990).
There are three major proteins found in the eye lens called α-, β- and γ- crystallins (Joseph Horwitz,
2000, 2003). The structure, biochemical and physiological properties as well as functionalities of
these crystallins have been studied in detail (Bloemendal, Toumadje, & Johnson Jr, 1999; Delaye
& Tardieu, 1983; Groenen, Merck, de Jong, & Bloemendal, 1994). The monomeric γ- crystallins
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are globular and the smallest with a molecular weight of about 20 kDa (Clark, Clark, David, &
Matsushima, 1999). In the case of β- crystallins, their subunits form oligomers with low molecular
weight species (βL – 60 kDa) and high molecular weight species (βH -160 kDa). Lastly, α-crystallin
is the most abundant and largest of the lens proteins (~ 18 nm in diameter) consisting anywhere
between 30-40 subunits with molecular weight ranging from 800-1200 kDa (Joseph Horwitz,
2003). In their native form, α-crystallin consists of two homologous subunits in a ratio of 3:1 - αA
and αB, with 173 and 175 amino acid residues, respectively. The molecular weight of these two
subunits is approximately 20 kDa.
Due to a very low protein turnover, crystallins are considered to be some of the longest-lived
proteins in the human body (Craig, Weissman, & Horwich, 1994; Garland, Russell, & Zigler Jr,
1988; van Kleef, de Jong, & Hoenders, 1975). Because of the long half-life, α-crystallin is prone
to irreversible modifications leading to changes in structure and function. The most commonly
observed post–translational modifications include photo-oxidization, deamidation, racemization,
phosphorylation, acetylation, glycation and age-dependent truncation (Hoehenwarter, Klose, &
Jungblut, 2006). Post-translational modifications alter protein-protein interactions and
subsequently destabilize and reduce the solubility of native crystallins.
The chaperone function of α- crystallin (Fig 10) has been well established and it has also been
found to prevent thermal aggregation of other proteins. Over a period of time, α-crystallin
undergoes irreversible post-translational modifications of which non-enzymatic glycation is
prominent especially in aging and diabetes. (R. F. Borkman, Knight, & Obi, 1996; Boyle &
Takemoto, 1994; Cherian & Abraham, 1995; Craig et al., 1994; Das & Surewicz, 1995; Ganea,
2001; Groenen et al., 1994; K. R. Heys, M. G. Friedrich, & R. J. Truscott, 2007; Hook & Harding,
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1996; J. Horwitz, 1992; Jakob, Gaestel, Engel, & Buchner, 1993; Khanova et al., 2005; Krishna
Sharma & Ortwerth, 1995; M. Kumar, Reddy, Kumar, Surolia, & Reddy, 2004; P. Kumar, Kumar,
& Reddy, 2007; B Raman, Ramakrishna, & Mohan Rao, 1995; Bakthisaran Raman & Rao, 1994;
Rao, Horwitz, & Zigler, 1993; Rekas et al., 2004; Srinivas, Raman, Rao, Ramakrishna, & Rao,
2003; Takemoto & Boyle, 1994; Tardieu, 1998; Van Montfort, Slingsby, & Vierling, 2002;
Vanhoudt, Abgar, Aerts, & Clauwaert, 2000a; K. Wang & Spector, 1995). As a result, the protein
slowly starts losing its chaperone ability and starts to aggregate.

Figure 10– Mechanism of chaperone action of α-crystallin
(http://pdslab.biochem.iisc.ernet.in/hspir/shsp.php)
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Although α-crystallin has been studied extensively, the quaternary structure of the native protein
has not been accurately elucidated. As a result, the location of protein modifications which are a
part of disease pathology are a matter of debate. There is no protein turnover in the eye lens. Hence,
the modifications that occur in the lens due to non-enzymatic glycation are permanent
(Mukhopadhyay, Kar, & Das, 2010). Reducing sugars react with basic amino acids of proteins to
form Schiff’s bases which undergo rearrangement to Amadori products and finally form advanced
glycation end-products (AGEs). These AGEs lead to loss of protein integrity, increase the
hydrophobicity and play an important role in protein denaturation (Monnier, 1989, 1990; Monnier
& Cerami, 1982; Monnier et al., 2008; Njoroge & Monnier, 1989; Stevens, Rouzer, Monnier, &
Cerami, 1978).
Protein denaturation is usually associated with formation of aggregates (Hollar, Parris, Hsieh, &
Cockley, 1995; Lindner & Demarez, 2009; Meredith, 2006). Formation of advanced glycation
endproducts is usually associated with protein crosslinking characterized by the growth of large
sized particles and hence is an optimum method for biophysical characterization based on particle
size. By studying the light scattering characteristics of protein aggregation, we can hypothesize the
effect of glycation on the protein and its role in the decrease of lens flexibility (presbyopia) as well
as the formation of a cataract.
Methylglyoxal (MGO) is a glycating agent that is generated non-enzymatically from the oxidation
and spontaneous dismutation of intermediates in the glycolysis pathway or enzymatic oxidation
reaction catalyzed by peroxidases (Bento, Marques, Fernandes, & Pereira, 2010; Ray, Dutta,
Halder, & Ray, 1994). MGO is known to be toxic and is known to interfere with cellular
mechanisms. MGO has been found to impair functions of mitochondria and also produce reactive
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oxygen species (Turk, Nemet, Varga-Defteardarovic, & Car, 2006). Another source of MGO in
the

body

is

deficiency

of

triose

phosphate

isomerase

leading

to

elevated

dihydroxyacetonephosphate (DHAP) levels observed in congenital hemolytic anemia and other
neurodegenerative diseases (Rosca et al., 2005). DHAP spontaneously disintegrates
to methylglyoxal which acts as a strong agent in the formation of advanced glycation end products
(AGEs). Because MGO reacts rapidly with the proteins, it is reasonable to assume that
modification by MGO would be a good in vitro model for studying the long term effects of aging
and diabetes in the lens (Fig 11).
The main aim of this project was to establish a correlation between the structural, molecular and
spectroscopic changes in the protein as it slowly denatures due to aggregation induced by nonenzymatic glycation to model aging and diabetes.
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Figure 11– Non-enzymatic glycation of proteins by simple sugars and dicarbonyl intermediates
(http://www.idb.hr/diabetologia/01no2-2.html)
Results
Dynamic light scattering (DLS) uses visible light to measure the time dependent fluctuations in
the scattering intensity to determine the translational diffusion coefficient (DT), and hydrodynamic
radius (RH) of a particle (Petta, Pharmakakis, Papatheodorou, & Yannopoulos, 2008). Aggregation
studies were performed by glycating 1mg/ml bovine α-crystallin with 1M glucose, 1M sucrose,
0.05 M glycolaldehyde and 10µM methyl glyoxal at 25oC for different time intervals as mentioned
in Chapter 2. The change in absorbance with glycolaldehyde and methyl glyoxal can be seen in
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Fig 12 and 13. The change in particle size, hydrodynamic radius, diffusion coefficients and
relaxation times of the dilute glycated protein samples were screened using DLS with a HeNe laser
at 633 nm as in Figures 14 -19.
Approximate molecular masses of modified and unmodified bovine α-crystallin samples were
determined using Static Light Scattering (SLS). A Zimm plot was constructed from the light
scattering intensities obtained at multiple angles (10, 20, 30, 40, 50, 60, 70, 80, 95, 100, 110 and
120) and different concentrations (0.125, 0.25, 0.5 and 1 mg/ml) to obtain the approximate
molecular weights (Fig 20). Small angle X-ray scattering (SAXS) was used to measure the interparticle distances as X-rays due to their shorter wavelength can interact with atoms (Fig 21 and
22) and also help us to understand the shape of the molecules (Lipfert & Doniach, 2007). These
light scattering techniques help us to study the physical changes in the protein and the effect of
modifications on the structure and shape of the protein.
The ANS dye is a valuable tool for the detection of protein surface hydrophobicity. Usually, the
dye has a low fluorescence yield, which is greatly enhanced on interaction with hydrophobic
surfaces. From the experimental data as shown in Fig 23, we can conclude that hydrophobicity
increases with time of glycation. Another important observation during this study is the spectral
shape exhibiting 2 peaks. This can be explained based on the fact that the fluorescence of ANS
dye is highly dependent on its environment. So the polarity of the micro-environment affects the
emission maxima of this molecule. Lee et al have shown that ANS dye shows an emission maxima
around 550 nm in a highly polar environment and a blue shift of around 50 nm in a less polar
environment (J. Lee & Robinson, 1985). Overall this study shows that the native state α-crystallin,
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upon glycation unfolds to expose the hydrophobic regions to the surrounding polar environment
and due to short range interactions, forms aggregates.
Progressive loss of soluble α-crystallin, associated with increased hydrophobicity and formation
of aggregates appears to be responsible for increasing the lens stiffness. Heys et al have shown
that the insoluble portion of the human lens proteins increases with aging (K. R. Heys et al., 2007).
Literature also suggests that heat induced denaturation of α-crystallin may be an important factor
in the etiology of presbyopia (K. R. Heys et al., 2007; Strenk et al., 2005). However, considering
the physiological conditions, non-enzymatic glycation seems to be the main culprit. Change in
solubility parameters of the lens proteins with increase in time of glycation have been studied by
screening the change in water and urea soluble portions using UV-Vis spectrophotometry at 280
nm. From Fig 24, we can observe that the glycation was associated with significant and progressive
insolubility of the lens proteins over the period of time.
Cataract and presbyopia can produce myopia due to a change in the refractive index of the
crystalline lens of the eye. The refractive index of native α-crystallin which is close to that of water
also changes as shown in Fig 25. The presence of high molecular weight aggregates and also
advanced glycation end-products lead to a change in both the scattering intensities as well as the
spectroscopic properties of the lens. Due to change in refractive index of the lens, the angle of the
refracted light changes leading to several focal points in close proximity on the retina causing
chromatic aberrations.
Secondary structure can be determined by circular dichroism spectroscopy in the "far-UV" spectral
region (190-250 nm). At these wavelengths the chromophore is the peptide bond, and the signal
arises when it is located in a regular, folded environment. α-crystallin is mainly made of beta sheets
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and hence the signal is observed as a downward trough at around 217 nm. With increase in period
of glycation, unfolding occurs leading to loss of beta sheets (Fig 26).
One of the major fluorophores in proteins is tryptophan. With increase in glycation, we observed
that the tryptophan fluorescence decreases (Fig 27). But, tryptophans in α-crystallin do not undergo
chemical modification due to Maillard reaction as there are no free amino groups. Tryptophan
fluorescence is a very valuable tool that can be applied to study folding/ unfolding, the effect of
environment and solvent exposure on the integrity of the protein. The fluorescence lifetimes of
tryptophan can be used to analyze the location of tryptophan and the possibility of short range
interactions (Table 4).
Discussion
Amplified concentrations of glycating agents in the body cause modifications in glycoproteins as
well as heat shock proteins which is a characteristic feature of aging and diseases like diabetes,
cancer and Alzheimer’s. The purpose of this study was a comparative evaluation of the AGE
formation in vitro through incubation of α-crystallin with various glycating agents like glucose,
sucrose, glycolaldehyde (GA) and methyl glyoxal (MGO). Study of tryptophan and AGE
fluorescence was used to evaluate the model for α-crystallin damage. The incubation of α-crystallin
with different glycating agents leads to the formation of aggregates over a period of time which
varies between minutes to months. The aggregates are associated with the destruction of native
state α-crystallin and formation of AGEs which are initiated by the condensation of basic amino
acids and sugars to form Schiff’s bases which undergo rearrangement to form Amadori products.
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Figure 12– Change in UV- Vis spectrum of α-crystallin after incubating with 0.05M
glycolaldehyde at 25oC over a period of 5 weeks
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Figure 13 – Change in UV- Vis absorbance of α-crystallin after incubating with 10 µM methyl
glyoxal at 25oC over a period of 9 hr.

55

Figure 14– Change in hydrodynamic diameter of α-crystallin after incubating with 1M glucose,
1M sucrose and 0.05M glycolaldehyde at 25oC over a period of 5 weeks
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Figure 15– Change in hydrodynamic diameter of α-crystallin after incubating with 10 µM methyl
glyoxal at 25oC over a period of 9 hr.
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Figure 16– Change in translational diffusion coefficients of α-crystallin after incubating with 1M
glucose, 1M sucrose and 0.05M glycolaldehyde at 25oC over a period of 5 weeks
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Figure 17– Change in translational diffusion coefficients (Diffusivity) of α-crystallin after
incubating with 10 µM methyl glyoxal at 25oC over a period of 9 hr.
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Figure 18– Change in relaxation times of α-crystallin after incubating with 1M glucose, 1M
sucrose and 0.05M glycolaldehyde at 25oC over a period of 5 weeks
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Figure 19– Change in relaxation times of α-crystallin after incubating with 10 µM methyl
glyoxal at 25oC over a period of 9 hr.
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Figure 20- Static Light Scattering data of 10 µM methyl glyoxal modified α-crystallin at 25oC
showing an increase in molecular mass with time of glycation
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Figure 21 - Small angle X-ray scattering data for measuring inter-particle distances in native
state α-crystallin
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Figure 22- Small angle X-ray scattering data for measuring inter-particle distances in glycated
α-crystallin
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Figure 23- Change in surface hydrophobicity of the native α-crystallin and 10 µM methyl
glyoxal modified α-crystallin over a period of 9 hr at 25oC

65

Figure 24- Changes in the amount of water soluble and insoluble fractions from the control calf
lens (0 hr) and 10 µM methyl glyoxal modified calf lens over a period of 9 hr at 25oC
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Figure 25- Change in refractive index due to formation of high molecular weight aggregates and
advanced glycation endproducts after glycating α-crystallin using 10 µM methyl glyoxal over a
period of 9 hr at 25oC
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Figure 26- Change in secondary structure of α-crystallin with increase in time of glycation using
10 µM methyl glyoxal over a period of 9 hr at 25oC
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Figure 27– Change in tryptophan fluorescence of α-crystallin after incubating with 10 µM
methyl glyoxal over a period of 9 hr at 25oC
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Table 4 - Changes in tryptophan lifetimes of α-crystallin after incubating with using 10µM
methyl glyoxal over a period of 9 hr at 25oC

Time of
glycation with
methyl glyoxal
(hr)

2

Lifetimes (ns) and relative contributions at time zero

Ӽ value

A1

τ1

A2

τ2

A3

τ3

0

16.1

1.3

53.4

4.3

30.5

9.6

0.97

0.5

12.3

1.5

48.5

4

39.2

9.8

1.11

1

14.7

1.5

44.4

5

40.9

9.8

1.08

3

16.1

1.7

42.3

4.9

39.5

9.8

1.21

6

17.4

1.8

48.2

4.9

34.4

10

1.01

9

18.2

2.3

43.7

3.5

40.2

10

0.99

Excitation wavelength – 295 nm
Emission wavelength – 370 nm
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Table 5-Amino acid sequence of Homo sapiens α-crystallin
α-crystallin A subunit

MDVTIQHPWFKRTLGPFYPSRLFDQFFGEGLFEYDLLPFLSSTISPYYRQSLFRTVLDSG
ISEVRSDRDKFVIFLDVKHFSPEDLTVKVQDDFVEIHGKHNERQDDHGYISREFHRRYRL
PSNVDQSALSCSLSADGMLTFCGPKIQTGLDATHAERAIPVSREEKPTSAPSS

α-crystallin B subunit

MDIAIHHPWIRRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTSLSPFYLRPPSFLRAPSW
FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGFISREF
HRKYRIPADVDPLTITSSLSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPKK
Black bold – αA- crystallin recognition sites on αB- crystallin
Red bold – chaperone site
Shaded region - α –crystallin domain
(Sreelakshmi, Santhoshkumar, Bhattacharyya, & Sharma, 2004)
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Figure 28- Positions of several residues in α-crystallin A model (left) and α-crystallin B model
(right)
(Guo, 2008)
The protein solutions have shown very good light scattering ability and the particle size of native
state α-crystallin was found to be 18 + 2 nm which was consistent with reports from literature
(Augusteyn & Koretz, 1987; Joseph Horwitz, 2003; Regini et al., 2004). When incubated with
glucose and sucrose, there was no effect on the particle size of α-crystallin over a period of 5
weeks. With glycolaldehyde, the particle size slowly increased from 18 to 350 nm over a period
of 5 weeks when incubated at 25oC. The reaction with MGO was relatively faster and the particle
size of the aggregates was around 350 nm within 9 hours. The change in the absorbance and
appearance of new excitation maxima with increase in time of glycation can be seen in Fig 12 and
13 for GA and MGO respectively. From this in vitro study, we observed that with an increase in
the particle size, the corresponding diffusivity of the protein decreases. The calculated diffusivity
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values from the in vitro study agree with the results obtained from the in vitro study for calculating
the protein diffusivity in rabbit lenses (Tanaka & Ishimoto, 1977). This study helped us to
determine that by measuring the light scattering from the lens and in turn particle size of the
aggregates, we can predict the formation of a cataract at a very early stage.
A large increase in the molecular weight of α-crystallin was followed using static light scattering
(Fig 20). Various research groups have hypothesized that cataract is a manifestation of high
molecular weight protein aggregates (Benedek, 1971; Trokel, 1962). Reports from the literature
indicate that the aggregates were formed by lens protein cross links linked by disulfide or covalent
bonds as monitored by gel electrophoresis and mass spectrometry (Prabhakaram, Ortwerth, &
Smith, 2000; Swamy, Tsai, Abraham, & Abraham, 1993). These aggregates are assumed to be
present randomly in the lens and have an ability to diffuse freely leading to increase of light
scattering and thereby change in the refractive index of the lens.
SAXS data is very useful in determining the inter-particle spacing and hence helps us to understand
the packing of α-crystallin in very high concentrations without super-aggregation or
crystallization. Previously, it has been reported that concentrated α-crystallin exhibited a spacing
of 14.8 nm by measuring the short range interactions (Delaye & Tardieu, 1983). Based on the Xray diffraction patterns from SAXS of native α-crystallin, Berger et al have reported that the
protein exhibits spherical symmetry (Siezen & Berger, 1978). Our study using 250 mg/ml pure αcrystallin has yielded a single reflection pattern at a Qmax of 0.042/Å which corresponds to a
spacing value of 14.9 nm as shown in Fig 21. It has been reported that the peak maxima, also called
iso-scattering point is the same irrespective of the concentration of the protein (Kawaguchi, 2004;
Regini et al., 2004).
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It has also been stated that increase in temperature is associated with thermal aggregation as well
as increase in the spacing (Vanhoudt et al., 2000a; Vanhoudt, Abgar, Aerts, & Clauwaert, 2000b;
Veretout, Delaye, & Tardieu, 1989). In order to study the effect of glycation on short range
interactions and spacing, X-ray scattering profiles of 250 mg/ml α-crystallin glycated with 10µM
methyl glyoxal were studied as shown in Fig 22. We observed a shift and formation of a weak
peak at lower scattering angles with a Qmax of 0.025/Å which gives a spacing value of 25.1 nm.
The weak scattering peak maxima might be due to loss of structural integrity of the protein and
spherical symmetry of the hetero-oligomeric complex.
Molecular chaperones are a class of proteins which help in the refolding of unfolded proteins to
their native state. In the absence of chaperones, these unfolded proteins may mutually associate
via exposed hydrophobic regions and precipitate out of solution. Chaperones have an important
role in protein folding and refolding by stabilizing the unfolded proteins, hence protecting them
from stress conditions. α-crystallin has been shown to function as a molecular chaperone in
preventing thermal aggregation of crystallins and other proteins. ANS fluorescence for surface
hydrophobicity has been used for the spectroscopic investigation of the high molecular weight
complex formed as a result of glycating bovine α-crystallin. From this study, we observed that the
surface hydrophobicity increases with the time of glycation providing more hydrophobic surfaces.
Previous literature shows that the chaperone ability of methyl glyoxal modified α-crystallin
increases initially. However, with increased time of glycation, the protein aggregates, loses its
structural integrity and chaperone ability (Cherian & Abraham, 1995; M. Kumar et al., 2004; P.
Kumar et al., 2007). As a result, other lens proteins are easily prone to stress leading to their
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damage. Our structural studies can explain the loss of chaperone activity reported in literature,
thereby establishing the relation between structure and function of alpha crystallin.
The formation of aggregates, change in inter-particle spacing and decreased protein diffusivity
also affect the physicochemical parameters of the proteins. The intricate complexation and
arrangement of α-crystallin is responsible for the transparency of the lens. As we can see in Fig
24, the soluble portion of the protein decreases drastically over time. At the same time, the
refractive index of native α-crystallin which has to be close to that of water also changes as shown
in Fig 25. Change in refractive index leads to increased light scattering in the eye and can be
hypothesized to be the reason for chromatic aberration that occurs with cataracts and in presbyopia.
Overall, the formation of high molecular weight aggregates due to glycation leads to a change in
both the scattering intensities as well as the spectroscopic properties of the lens.
Far UV circular dichroism (CD) spectra reflect the changes in secondary structure of the proteins.
Both the native state and glycated α-crystallin showed a minimum at 217 nm which indicates beta
sheets (Fig 26). However, with the progression of glycation, α-crystallin showed a considerable
decrease in the negative ellipticity and a tendency to shift towards the left. Loss of structural
stability due to the loss of beta sheets can be concluded from the CD data. This can be explained
by the formation of high molecular weight aggregates and increase in surface hydrophobicity. This
study is consistent with reported literature about the loss of beta sheets (B Raman et al., 1995; B.
Raman, Ramakrishna, & Rao, 1997; Bakthisaran Raman & Rao, 1994). Large aromatic residues
(Tyr, Phe and Trp) and β-branched amino acids (Thr, Val, Ile) are highly favored in the beta sheets.
Presence of these residues in the random coil can explain the increase in hydrophobicity of the
protein associated with the loss of beta sheets.

75

Tryptophan has a very strong fluorescence in the proteins. The residues which are buried in the
hydrophobic core of proteins can have spectra which are shifted by 10 to 20 nm compared to
tryptophans on the surface of the protein (Lakowicz & Geddes, 1991). Tryptophan fluorescence
can be quenched due to microenvironments. In case of α-crystallin, the unmodified protein seems
to have more fluorescence than the modified as shown in Figure 27. The magnitude of fluorescence
intensity can serve as a probe to explain the perturbations occurring in the native state. The
wavelength maxima of tryptophan fluorescence shifted on modification indicating a change in the
microenvironment which can be confirmed by surface hydrophobicity measurements. In αcrystallin, tryptophans are not located at the N-terminus and hence do not have a free amino group
to participate in the Maillard reaction. Dillon et al have studied extensively on the photo
degradation products of alpha crystallin and showed that they were primarily from tryptophan
oxidation (J. Dillon & Atherton, 1990; Ervin et al., 2001; E. L. Finley et al., 1997; M. McDermott
et al., 1991).
Another interesting aspect of tryptophan fluorescence spectral profiles is a shift in the isosbestic
point of the spectra. Usually, the presence of an isosbestic point indicates that only two species
that vary in concentration contribute to the absorption around the isosbestic point. If a third
molecule is participating in the process, the spectra typically intersect at varying wavelengths as
concentrations change, creating the impression that the isosbestic point is 'out of focus', or that it
will shift as conditions change (Moore, 1961). The reason for this is that the different compounds
have varying extinction coefficients at one particular wavelength. Tryptophan oxidation products
have spectral profiles similar to AGEs with varying extinction coefficients (R. Borkman, Tassin,
& Lerman, 1980; R. F. Borkman, Tassin, & Lerman, 1981; R. B. Kurzel, M. Wolbarsht, B. S.
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Yamanashi, G. W. Staton, & R. F. Borkman, 1973). This helps us to explain the decrease in
tryptophan fluorescence with increase in the time of glycation.
Advanced glycation end-products have a characteristic fluorescence and seem to be excited in the
spectral region of tryptophan emission. Generation of AGEs can be associated with oxidative
stress, tobacco smoking and weakened detoxification of AGE precursors. Compared to sugars like
glucose and sucrose, the dicarbonyl intermediates cause a lot of damage. This indicates that the
rate of AGE formation also depends on the rate of breakdown of sugars into the highly reactive
intermediates which in turn is dependent on many intrinsic and extrinsic factors (Babett Bartling
et al., 2011; Simm et al., 2014). The change in AGE fluorescence with decrease in tryptophan
fluorescence can be observed in Fig 27. Further detailed studies on AGE fluorescence can be seen
in Chapter 4.
Tryptophan (Trp) lifetime measurements can be used to give a rough idea about the changes in the
microenvironments. Tryptophan fluorescence is a very valuable tool that can be applied to study
folding/ unfolding, the effect of environment and solvent exposure on the integrity of the protein.
The fluorescence lifetimes of tryptophan can be used to analyze the location of tryptophan and the
possibility of short range interactions. Gaillard et al have shown that the fluorescence of αcrystallin is predominantly due to the Trp 9 in both A and B chains while the Trp 60 present in the
B chain is buried from exposure (Mandal et al., 2000). However, once the process of glycation
begins, it seems that the tryptophans are completely exposed to the surrounding aqueous medium.
This can be confirmed from the lifetime measurements as in Table 4, as we do not observe any
change in the lifetimes with time of glycation. But, the measurements hint at a possibility that the
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tryptophan residues undergo a shift in their position once the protein starts to unfold and aggregate
leading to the formation of water insoluble residues.
The Trp residues in peptides generally show fluorescence emission spectra, with a peak around the
340-370 nm region, similar to the Trp residues in aqueous media or in fully denatured proteins
(Lakowicz & Geddes, 1991; Sreelakshmi et al., 2004). However, interaction of peptides possessing
Trp residues with proteins would result in diminished exposure of the peptide Trp (as seen in Trp
60) to the aqueous environment with a concomitant blue shift in the fluorescence emission
maxima. Simulation studies have shown that, although Trp 60 is exposed to solvent in the α-B
subunit, it is buried in the dimer models, located at the interacting interface of the subunits (Guo,
2008). Using LCMS and isotopic labeling, Kielmas et al have shown that K70, K88, K92, K99,
K103,K145,K150 and K166 are the lysine glycation targets on α-crystallin (Kielmas et al., 2015).
Gangadharaiah et al have reported that R12, R21, R54, R65, R69, R103, R112, R117, R119, R157
and R163 are arginine glycation sites on α-crystallin (Gangadhariah et al., 2010). Based on these
target sites of glycation, we can assume that modifications occur within the vicinity of the
tryptophan (Trp 60) exposing it to different microenvironments as they are chemically modified.
It has been predicted that intraocular fluid velocity is approximately around 1.7 x 10-3 m/s (Beebe
& Truscott, 2010; P. J. Donaldson, Musil, & Mathias, 2010). This flow velocity is extremely slow
considering the nutrients transported increase the viscosity of the fluid. This is in tune with the
very low diffusion coefficient data obtained from dynamic light scattering data. Based on that, we
can explain that glucose and sucrose pass through the lens but do not spontaneously react with the
proteins. On the other hand, glycolytic intermediates like methyl glyoxal are extremely reactive
and start forming Schiff’s bases when they come in contact with the protein and instantaneously
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lead to the formation of AGEs. Also, the aggregates cause an irreparable damage to the intricate
protein network causing opacification which is most commonly observed in case of cataracts.
Overall, this study helped us to determine spectroscopic and biophysical properties like particle
size and AGE fluorescence characteristic to aging and diabetes. We have examined the effect of
protein aggregation on the structure and in turn, function of heat shock proteins in the lens. While
the crystal structure of α-crystallin still remains a controversy, our study helped to lay a ground to
understand the glycation induced damage to α-crystallin and other heat shock proteins. This will
in turn help instigate a hypothesis for developing biomarkers for non-invasive diagnosis of diabetes
and future pharmaceutical arbitration to suppress the protein aggregation to provide treatment for
many serious diseases.
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CHAPTER 4 - EARLY DIAGNOSIS OF DIABETES THROUGH THE EYE
Introduction
Diabetes mellitus is an endocrinal metabolic disorder characterized by high blood sugar levels
which gives rise to complications in various organs of the body. The disorder arises due to
inadequate insulin production, or because the body's cells are non-responsive to insulin, or both
(Wilcox, 2005). Globally, about 382 million people have diabetes, of which around 46% remain
undiagnosed (Fig 29). Diabetes mellitus starts a vicious cycle of diseases affecting the heart,
kidneys, eyes and the nervous system. The high blood sugar levels have been observed to cause
damage to small blood vessels in these organs by destroying their structure (de la Maza et al.,
2012; Xu & Zou, 2009). The total estimated cost of diagnosed diabetes in 2012 is $245 billion
which increased to $548 billion in 2013 as in Fig 30 (Dall et al., 2014). Overall, the number of
diabetics as well as the expenditure including direct and indirect costs have been increasing
drastically.
Currently, there are several methods used for the diagnosis of diabetes as in Table 6. Measurement
of glycated proteins, primarily glycated hemoglobin (HbA1c or A1C), has been widely used for
routine long-term monitoring of glucose control and as a measure of risk for the development of
diabetes complications. The A1C test measures your average blood glucose for the past 2 to 3
months and if the values are greater than or equal to 6.5%, the person is considered diabetic. The
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Fasting Plasma Glucose (FPG) and Oral Glucose Tolerance (OGT) tests measure the blood sugar
levels after fasting and having a sweet drink respectively. Values greater than or equal to 126 mg/dl
and 200 mg/dl are considered diabetic in FPG and OGT respectively (Sacks, 2003; Sacks et al.,
2002).

Figure 29– Prediction of the number of undiagnosed diabetic cases globally
(Aguiree et al., 2013; Atlas, 2000)

81

Figure 30– Global increase in expenditure due to diabetes
(Aguiree et al., 2013; Atlas, 2000)
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Table 6- Criteria for the diagnosis of diabetes and of increased risk for diabetes [prediabetes]/Impaired Fasting Glucose [IFG] adopted from ADA—Clinical Practice
Recommendations [Diabetes Care, 36 [S1], 2013

Although, these tests give accurate results in diabetic patients, they have their exceptions. The
blood glucose levels in the body fluctuate depending on the meals, exercise, sickness, and stress.
It has also been shown that different diagnostic tests might give varying results and not agree with
one another (Sacks, 2003). The glycation of hemoglobin occurs at several amino acid residues and,
as a result, several adducts of hemoglobin A (HbA) and various sugars are formed by the nonenzymatic post-translational glycation process. This process involves the formation of a labile
Schiff base intermediate followed by the Amadori rearrangement. The reaction is slow, irreparable,
and the reaction rate depends on the ambient glucose concentration (Cohen et al., 2008; Cohen,
Haggerty, & Herman, 2010; Panzer, Graninger, Kronik, Bettelheim, & Lechner, 1983). Also, these
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tests do not take into consideration that the proteins, especially in the vasculature, have rapid
turnover and hence are not always the same (Dobler, Ahmed, Song, Eboigbodin, & Thornalley,
2006).
According to International Expert Committee, HbA1c has been recommended as an accurate and
precise marker for diabetes based on advances in instrumentation and standardization. The theory
behind the A1C test is that our red blood cells live an average of three months. So, if we measure
the amount of glycated hemoglobin, it will give an idea of glycation that occurred over the last 3
months. But, research has shown that the lifetime of red blood cells of diabetics is comparatively
shorter than that of non-diabetics (Cohen et al., 2010). This means that the hemoglobin turnover
is faster in case of diabetics and hence is a major disadvantage for diagnosing the patients in their
early stages (Reynolds, Smellie, & Twomey, 2006; Tran, Silva, & Petrovsky, 2004). Also, it has
been reported that people with hemoglobin variants like HbC and HbS have shown false negatives
(Bry, Chen, & Sacks, 2001; W. L. Roberts et al., 2005). A false elevated A1C level has been
observed in certain clinical situations that affect RBC life span with iron deficiency anemia, high
alcohol consumption and hypertriglyceridemia. Other cases which have shown false results
include patients with kidney failure and liver disease (Association, 2008).
The eye lens is avascular and constitutes a dense matrix of closely packed proteins. α-crystallin is
a major water soluble small heat shock protein (~ 45%) found in the eye lens. It is isolated from
vertebrate eye lens as a polydisperse, hetero-oligomeric complex of approximately 800 kDa,
consisting of 35–40 subunits. It is made up of two distinct sub-units – A and B in the ratio of 3:1
respectively. Extensive research has confirmed its chaperone function in protecting other proteins
and crystallins from thermal aggregation (B Raman, Ramakrishna, & Mohan Rao, 1995; Siezen,
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Bindels, & Hoenders, 1980). This in turn helps in maintaining the transparency of the eye lens.
Recently, it has been observed that α-crystallin sub-units are not restricted to the eye lens but also
expressed in other non-lenticular tissues like retina, heart, brain and kidneys. While αA is mostly
restricted to the lens and retina, it has been reported that αB subunit is expressed ubiquitously in
cells undergoing stress (Berger & Vanderkooi, 1990; De Jong, Leunissen, & Voorter, 1993; Deng
et al., 2010; Fort & Lampi, 2011; Horwitz, 1992, 2000, 2003; B Raman et al., 1995; Bakthisaran
Raman & Rao, 1994; Spector, Freund, Li, & Augusteyn, 1971; Urbak & Vorum, 2011).
An important biomarker for diabetes related diseases is the formation of advanced glycation
endproducts (AGEs). AGEs are formed due to non-enzymatic glycation of the proteins on
exposure to open chain sugars and dicarbonyl intermediates. Hyperglycemic conditions, oxidative
and thermal stress lead to the formation of Schiff’s bases with basic amino acids like lysine and
arginine (Ahmed, 2005; Rabbani & Thornalley, 2012; Thomas, 2011). Further, Amadori products
are formed due to rearrangement of the Schiff’s bases when highly reactive carbonyl intermediates
accumulate and attack the amino and guanidine groups on the proteins (Gangadhariah et al., 2010;
Monnier et al., 2008; Rosca, Monnier, Szweda, & Weiss, 2002; Rosca et al., 2005). Unlike
hemoglobin and albumin, the heat shock proteins have long half –lives and very low turnover
(Craig, Weissman, & Horwich, 1994; Parsell et al., 1993; Shetty, Jung, Watrasiewicz, & James,
1979; Sterling, 1951). As a result, the accumulation of glycation products over a long period of
time is of quantitative significance.
The main aim of this project is to show that by screening the changes in the lens proteins and,
consequently, the intact lens, we can identify non-invasive spectroscopic biomarkers for the early
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diagnosis of diabetes mellitus. The appearance of these biomarkers will, in turn, act as a standard
diagnostic test for commencing the treatment regimen, thereby preventing further complications.
Results
Figures 31 - 34 provide preliminary case studies comparing the spectroscopic hotspots in lens
autofluorescence for similar aged donor non-diabetic and diabetic lenses. Emission spectra from
the protein model α-crystallin with increase in time of glycation were recorded for the excitation
wavelengths set at 340, 370 and 435 nm. By excitation at 340 and 370 nm, emission spectra showed
one distinct peak (Fig. 35 and 36) located at about 440 and 460 nm compatible with the absorption
caused by AGEs. A broad band was observed at 500 nm by increasing the excitation wavelength
to 435 nm (Fig 37). Fluorescence emission spectra were also recorded from intact lenses from
donors with and without diabetics. Qualitatively, the shape and peak value of the emission spectra
excited at the same wavelength were very similar for α-crystallin and the intact lenses (Fig. 38 and
39), indicating the ﬂuorophore formation in lens crystallins.
Time-resolved ﬂuorescence measurements were analyzed from the fluorescence decay assuming
that the model followed a triple exponential fit. In the case of 340 and 370 nm excitation, one or
two exponential functions did not provide an acceptable ﬁt, as judged by autocorrelation, number
of weighted residuals and Durbin Watson parameters. The lifetimes and their relative contributions
were determined at excitation wavelengths - 340 and 370 nm as seen in Tables 7 and 8. The overall
ﬂuorescence lifetimes were longer for excitation at 370 nm but they did not change with time of
glycation in either cases. Table 9 shows the fluorescence lifetimes from unmodified and modified
α-crystallin at an excitation wavelength of 435 nm. Here, we can see noticeable trends in the
lifetimes with glycation of the protein. In the visible region, unmodified α-crystallin showed no
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fluorescence and therefore, no lifetimes. However, for glycated α-crystallin, we could see new
shorter and longer lifetimes with increase in the time of glycation.
Steady state and time resolved fluorescence measurements were collected from intact non-diabetic
and diabetic lenses ranging from 6 to 92 year old donors. An illustration of difference in the
spectral profiles from donor lenses of 3 different age groups can be seen in Fig 38 and 39. Table
10 provides an overall summary of time resolved fluorescence lifetimes obtained at 340 nm from
various donor lenses. A sample of time resolved fluorescence data comparisons from non-diabetic
and diabetic donor lenses from different age groups can be observed in Tables 11 – 14. Table 15
provides an overall summary of time resolved fluorescence lifetimes obtained by excitation at 435
nm from various donor lenses. From this data, it can be seen that the distribution of lifetimes and
their individual contribution to the total fluorescence at 435 nm excitation wavelength is very
different for non-diabetic and diabetic donor lenses. While the younger non-diabetics did not show
any fluorescence, older non-diabetics showed one fluorescence lifetime around 4.7 ns. In the
diabetic lenses from younger donors, the time resolved fluorescence decay spectra showed a very
good fit with a double exponential decay with lifetimes around 4.6 and 17 ns. The decay spectra
from older diabetic donor lenses gave a good fit with triple exponential decay with lifetimes around
1.4, 4.5 and 16 ns.
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Figure 31– Comparison of steady state fluorescence hotspots between 20 yr old non-diabetic and
18 yr old type I diabetic
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Figure 32– Comparison of steady state fluorescence hotspots between 42 yr old non-diabetic and
42 yr old type II diabetic
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Figure 33– Comparison of steady state fluorescence hotspots between 56 yr old non-diabetic and
56 yr old with diabetic retinopathy
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Figure 34– Comparison of steady state fluorescence hotspots between 64 yr old non-diabetic and
67 yr old with cataract
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Figure 35– Steady state fluorescence spectra of α-crystallin with increase in time of glycation at
an excitation wavelength of 340 nm
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Figure 36– Steady state fluorescence spectra of α-crystallin with increase in time of glycation at
an excitation wavelength of 370 nm
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Figure 37– Steady state fluorescence spectra of alpha crystallin with increase in time of glycation
at an excitation wavelength of 435 nm
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Figure 38 - Comparison of steady state fluorescence measurements at an excitation wavelength of
340 nm. Comparison of steady state fluorescence measurements at an excitation wavelength of
340 nm between non-diabetic (56 and 77 yr old) and diabetic (59 and 70 yr old) human donor
lenses. In the inset, comparison of steady state fluorescence measurements at an excitation
wavelength of 340 nm from non-diabetic human lenses from donors - 20, 56 and 77 year old at the
time of death can be observed.
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Figure 39 - Comparison of steady state fluorescence measurements at an excitation wavelength of
435 nm. Comparison of steady state fluorescence measurements at an excitation wavelength of
435 nm between non-diabetic (56 and 77 yr old) and diabetic (59 and 70 yr old) human donor
lenses. In the inset, comparison of steady state fluorescence measurements at an excitation
wavelength of 435 nm from non-diabetic human lenses from donors - 20, 56 and 77 year old at the
time of death can be observed.
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Table 7 - Time resolved fluorescence lifetimes from glycated alpha crystallin by excitation at
340 nm and emission maxima between 420-440 nm

Time of
glycation
with
MGO
(days)

Lifetimes, Ʈ (ns) and

A1

ᶍ2 value

Relative contributions at time zero, A (%)
Ʈ1
A2
Ʈ2
A3

Durbin –
Watson
parameter

Ʈ3

Control

70.5 + 1.5

0.5 + 0.04

18.9 + 1.9

2.4 + 0.02

10.6 + 3.2

7.2 + 0.17

0.96

2.1

10

65.5 + 1.4

0.6 + 0.15

22.1 + 1.2

2.2 + 0.3

12.4 + 0.8

7.2 + 0.5

1.04

1.87

20

54.8 + 2.9

0.6 + 0.01

29.5 + 1.7

2.5 + 0.07

15.7 + 1.2

7.6 + 0.02

0.98

1.8

30

49.8 + 2.9

0.7 + 0.08

34 + 2.7

2.8 + 0.3

16.2 + 2.8

7.9 + 0.32

1.031

2.12

40

45.3 + 0.1

0.5 + 0.1

37.7 + 2.1

2.3 + 0.2

17 + 0.95

7.9 + 0.1

1.002

1.94

50

34.9 + 1.1

0.7 + 0.1

45.2 + 1.2

2.4 + 0.3

19.9 + 0.7

7.85 + 0.5

0.954

1.81

60

28.8 + 4.5

0.76 + 0.2

50.1 + 3.2

2.78 + 0.4

21.1 + 1.7

8 + 0.6

0.97

2.01
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Table 8 - Time resolved fluorescence lifetimes from glycated alpha crystallin by excitation at 370
nm and emission maxima between 440-460 nm

Time of
glycation
with
MGO
(days)

Lifetimes, Ʈ (ns) and
Relative contributions at time zero, A (%)

ᶍ2 value

Durbin –
Watson
parameter

A1

Ʈ1

A2

Ʈ2

A3

Ʈ3

40.5 + 1.8

1.1 + 0.1

39.2+ 0.1

3.6 + 0.17

20.3 + 2.6

10.1 + 1.7

0.97

1.82

41.9 + 1.4

1.2+ 0.2

37.9+ 0.01

3.7 + 0.14

20.2 + 0.6

10.6 + 0.7

0.997

1.945

42.8 + 2.9

1.3 + 0.31

36.1 +1.6

3.67+ 0.1

21.1 + 0.7

10.5 + 1.7

0.99

1.85

44.1 + 0.3

1.16+ 0.2

34.1 + 0.2

3.55+ 0.09

21.8+ 0.6

10.6 + 0.5

1.01

1.801

45.1 + 0.2

1.2 + 0.11

31.7 +0.31

3.6 + 0.24

23.2+ 0.01

10 + 0.6

0.985

1.917

49.2 + 0.2

1.0 + 0.43

29.1 + 0.3

3.6 + 0.19

21.7+ 2.7

10.7 + 0.3

1.013

1.95

51.6 + 0.2

1.1 + 0.39

27.3 +0.64

3.4 + 0.41

21.1 + 0.3

10.6 + 1.4

0.988

1.9

Control

10

20

30

40

50

60
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Table 9 - Time resolved fluorescence lifetimes from glycated alpha crystallin by excitation at 435
nm and emission maxima between 500-510 nm

Lifetimes, Ʈ (ns) and
Relative contributions at time zero, A (%)

Time of
glycation
with
MGO
(days)

Ʈ1

A2

Ʈ2

A3

Ʈ3

-

-

-

-

-

-

-

-

-

-

100

4.7 + 0.04

-

-

0.999

1.635

-

-

96.11 +1.6

4.76+ 0.2

3.89+0.06

19.5 + 1.7

0.985

1.75

44.1 + 0.3

1.67+ 0.1

20.1 + 0.2

4.51+ 0.09

35.8+ 0.6

17.6 + 0.5

1.07

1.81

45.1 + 0.2

1.6 + 0.11

19.7 +0.31

4.6 + 0.04

35.2+ 0.01

17 + 0.6

1.075

1.871

58.2 + 0.2

1.4 + 0.43

30.1 + 0.3

4.6 + 0.14

11.8+ 2.7

16.7 + 0.3

1.03

1.85

51.6 + 0.2

1.5 + 0.31

42.3 +0.64

4.4 + 0.43

6.07+ 0.3

15.6 + 1.4

0.987

1.961

10

20

40

50

60

Durbin –
Watson
parameter

A1

Control

30

ᶍ2 value

Table 10 - Summary for time resolved fluorescence lifetimes from human donor lenses by
excitation at 340 nm and emission maxima between 420-440 nm
ᶍ2
value

Lifetimes, Ʈ (ns) and

Type of
donor
lens
A1

Relative contributions at time zero, A (%)
Ʈ1
A2
Ʈ2
A3

Durbin –
Watson
parameter

Ʈ3

Nondiabetic
(N = 35)

52-65 %

0.62 + 0.1

20-33 %

2.6 + 0.14

13-21 %

7.6 + 0.2

1.04

1.97

Diabetic
(N = 9)

38-49 %

0.66 + 0.1

37-45 %

2.3 + 0.1

12- 19 %

7.6 + 0.12

1.01

1.9
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Table 11 - Comparison of time resolved fluorescence lifetimes from 20 yr old non-diabetic and 18
yr old type I diabetic human donor lenses by excitation at 435 nm and emission maxima between
500-510 nm

Lifetimes, Ʈ (ns) and

Type of
donor
lens
A1
Nondiabetic
(20 yr)
Diabetic
(18 yr)

Relative contributions at time zero, A (%)
Ʈ1
A2
Ʈ2
A3

ᶍ2 value

Durbin –
Watson
parameter

-

-

Ʈ3

-

-

-

-

-

-

-

-

80.4± 0.01

4.7 ± 0.07

19.6± 0.1

16.9 + 0.1

0.997

1.981

Table 12 - Comparison of time resolved fluorescence lifetimes from 42 yr old non-diabetic and 42
yr old type II diabetic human donor lenses by excitation at 435 nm and emission maxima between
500-510 nm

A1
Nondiabetic
(42 yr)
Diabetic
(42 yr)

ᶍ2 value

Lifetimes, Ʈ (ns) and

Type of
donor
lens

Relative contributions at time zero, A (%)
Ʈ1
A2
Ʈ2
A3

-

-

-

-

-

84.1± 2.2

-

4.2 ± 0.77

-

15.9± 3.2

Durbin –
Watson
parameter

Ʈ3

-

17.1 + 0.5

-

1.073

-

1.74
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Table 13 - Comparison of time resolved fluorescence lifetimes from donor lenses of 56 yr old nondiabetic and 56 yr old with diabetic retinopathy by excitation at 435 nm and emission maxima
between 500-510 nm

Lifetimes, Ʈ (ns) and

Type of
donor
lens
A1
Nondiabetic
(56 yr)

Diabetic
(56 yr)

Relative contributions at time zero, A (%)
Ʈ1
A2
Ʈ2
A3

ᶍ2 value

Durbin –
Watson
parameter

Ʈ3

-

-

100

4.5 + 0.17

-

-

1.07

1.79

-

-

51.4 + 0.8

4.6 + 0.11

48.6 + 0.2

17 + 0.17

1.073

1.74

Table 14 - Comparison of time resolved fluorescence lifetimes from donor lenses of 64 yr old nondiabetic and 67 yr old with cataract by excitation at 435 nm and emission maxima between 500510 nm

Lifetimes, Ʈ (ns) and

Type of
donor
lens
A1
Nondiabetic
(64 yr)

Diabetic
(67 yr)

Relative contributions at time zero, A (%)
Ʈ1
A2
Ʈ2
A3

ᶍ2 value

Durbin –
Watson
parameter

Ʈ3

-

-

100

4.76 + 0.1

-

-

0.992

1.86

39 + 1.9

1.4 + 0.2

41.9 + 0.5

4.5 + 0.3

20.1 + 1.2

15.6 + 0.9

1.073

1.94
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Table 15 - Summary for time resolved fluorescence lifetimes from human donor lenses by
excitation at 435 nm and emission maxima between 500-510 nm

Type of
donor
lens
Nondiabetic*
(< 45 yr)
(N = 10)
Nondiabetic
( > 45 yr)
( N=34)
Diabetic
(< 45 yr)
(N = 4)

Diabetic
(>45 yr)
(N = 5)

Lifetimes, Ʈ (ns) and
Relative contributions at time zero, A (%)

ᶍ2
value

Durbin –
Watson
parameter

A1

Ʈ1

A2

Ʈ2

A3

Ʈ3

-

-

-

-

-

-

-

-

-

-

100

4.76+0.02

-

-

0.967

2.14

-

-

58.1 + 0.5

4.6 + 0.14

41.9 + 0.2

16.2 + 0.05

0.992

1.76

37.1 + 4.8

1.6 + 0.07

33.9 + 5.2

4.3 + 0.02

29 + 2.6

15.1 + 0.01

0.985

2.06

*No disease conditions and ocular history
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Discussion
Non enzymatic glycation of the proteins is a characteristic feature of aging and diseases like
diabetes (Mukhopadhyay et al., 2010). This reaction leads to the formation of advanced glycation
endproducts on the proteins leading to prolific damage to their structural integrity. Advanced
glycation end-products have been shown to exhibit very strong fluorescence as the degree of
glycation enhances (Bursell & Yu, 1990; Spector et al., 1971). The change in fluorescence
intensity can serve as a probe to explain the alterations occurring in the native state protein and
also provides information on the degree of damage done to the protein.
The augmentation of fluorescence from glycated protein was observed by screening the
fluorescence emission by excitation in UV-A region at 340, 370 nm as well as visible region at
435 nm. Oxidative stress, tobacco smoking and weakened detoxification of AGE precursors have
also been reported as some of the reasons for increase in AGE production (B. Bartling et al., 2011;
Line Kessel, 2004). Other risk factor for high AGE production is a diet with high sugar content
(Vlassara & Palace, 2002). Increased AGE levels have also been observed to be major biomarkers
in pathophysiology of various degenerative diseases (Stirban et al., 2006; Uribarri et al., 2007).
Compared to sugars like glucose and sucrose, the dicarbonyl intermediates are much more
reactive(Rabbani & Thornalley, 2012). The rate of AGE formation depends on the rate of sugar
breakdown into highly reactive intermediates like methyl glyoxal which in turn depends on many
intrinsic and extrinsic factors like defective glycolysis pathway, enzymatic peroxidation,
deficiency of triose phosphate isomerase, smoking and consumption of high sugar diet (Dakin &
Dudley, 1913; Kalapos, 1999; McLellan & Thornalley, 1994; Rabbani & Thornalley, 2012;
Thornalley, 1996).
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Steady state fluorescence emission spectra were recorded from intact human lenses by excitation
at 340, 370 and 435 nm. At 340 and 370 nm, the shape and emission maxima were the same in
case of non-diabetic lenses but showed a red shift in case of diabetic lenses. However, with
increasing excitation wavelength, the peak emission gradually shifted to longer wavelengths. At
435 nm, we observed fluorescence was only in the case of lenses from diabetic donors but not in
the non-diabetics. Steady state fluorescence measurements give valuable information about the
spectral profiles, but they cannot be quantified. Fluorescence is dependent on various factors like
concentration of the fluorophores, optical density and instrumental parameters which are not
constant for all the samples. Another disadvantage of using fluorescence intensities as a standard
is the possibility of inner filter effect or self-quenching. This can be seen as a problem especially
in case of intact lenses where the protein concentration is very high and the concentration of AGEs
increases with age and diabetes (J. N. Liang, 1990).
A better and more reliable alternative would be to measure the lifetimes of AGE fluorophores. The
fluorescence lifetime is an intrinsic molecular property which is independent of concentration,
hence, gives a consistent, dynamic depiction of the fluorophores (Bastiaens & Squire, 1999;
Lakowicz & Geddes, 1991; Lakowicz, Koen, Szmacinski, Gryczynski, & Kuśba, 1994).
Measuring the fluorescence lifetimes is valuable as the fluorescence decay occurs at a nanosecond
time scale and is highly influenced by the interacting molecules as well as their microenvironment
(Beechem & Brand, 1985; Striker, Subramaniam, Seidel, & Volkmer, 1999). The time resolved
fluorescence decay lifetimes are very specific and also help us to study multiple parameters which
is not possible with the steady state measurements.
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The fluorescence lifetimes of glycated α-crystallin, when excited at 340, 370 and 435 nm can be
seen in Tables 6, 7 and 8 respectively. The success of the fit was evaluated using reduced chisquare value and Durbin-Watson parameter. The reduced chi square value was considered good at
values between 0.9 – 1.2. The Durbin-Watson parameter was 1.6, 1.7 and 1.8 or more for a one,
two and three exponential decay respectively for successful evaluation of the fit. Similarly, the
time resolved fluorescence decay curves from intact lenses at 340 and 435 nm were collected to
obtain the lifetimes of the fluorophores as seen in Tables 9 and 14 respectively.
At excitation wavelengths of 340 and 370 nm, we have seen that the emission spectra from
glycated α-crystallin have shown a red shift of the emission maxima from 420 nm to around 445
nm with increase in extent of glycation. The ﬂuorescence decay observed when the excitation
wavelength is increased to 370 nm can also be ﬁtted to a sum of three exponential functions, but
the three lifetimes are now overall longer. The shift in the fluorescence emission maxima with
time has always been attributed to the formation of new crosslinks within the protein which affects
its conformation and in turn the orientation of the fluorophores in their micro-environments. Kessel
et al have reported that the main contributing fluorophore when excited in the UV region is
argpyrimidine (L. Kessel, S. Kalinin, R. H. Nagaraj, M. Larsen, & L. B. Å. Johansson, 2002; L.
Kessel, S. Kalinin, V. Soroka, M. Larsen, & L. B. Johansson, 2005; L Kessel, Larsen, & Group,
2003). They have studied the effect of different microenvironments on the emission spectrum and
fluorescence lifetimes to explain the red shift. The similarities between our results and their
reported data helped us to validate our work (L. Kessel, S. Kalinin, R. H. Nagaraj, M. Larsen, &
L. B. Johansson, 2002; L. Kessel, S. Kalinin, V. Soroka, M. Larsen, & L. B. Å. Johansson, 2005).
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However, as we can observe, the fluorescence lifetimes did not change with time of glycation.
This shows that the fluorescence lifetimes measured in this region are not affected by glycation.
From previous literature, we can infer that the lifetimes measured by excitation at 340 nm are
primarily from tryptophan (R. Borkman et al., 1980; R. F. Borkman, 1984; R. F. Borkman, Douhal,
& Yoshihara, 1993; R. F. Borkman & Lerman, 1978; R. Kurzel et al., 1973; Mandal et al., 2000;
Roberts, Atherton, Gaillard, & Dillon, 1995). Studies show that, in the UV-region, there are
various fluorophores which include photo-degradation products of tryptophan like N-formyl
kynurenine, anthranilic acid, kynurenine, 3-hydroxykynurenine, harmane and several advanced
glycation end-products (Atherton, Lambert, Schultz, Williams, & Zigman, 1999; Berger &
Vanderkooi, 1990; R. Borkman et al., 1980; R. F. Borkman, 1984; R. F. Borkman, Dalrymple, &
Lerman, 1977; R. F. Borkman et al., 1993; R. F. Borkman & Lerman, 1978; R. F. Borkman et al.,
1981; Bursell & Yu, 1990; J. Dillon & Atherton, 1990; Line Kessel et al., 2002; L. Kessel et al.,
2005; R. Kurzel et al., 1973; Sidney Lerman & Borkman, 1976; S Lerman & Borkman, 1978; S
Lerman, Kuck Jr, Borkman, & Saker, 1976; S Lerman, Yamanashi, Palmer, Roark, & Borkman,
1978; Mandal et al., 2000; Vigneshwaran, Bijukumar, Karmakar, Anand, & Misra, 2005). Further,
evidence shows that AGEs exhibit photosensitizer activity in the UV region leading to the rapid
oxidation of tryptophan (Argirova & Breipohl, 2002; de La Rochette, Birlouez-Aragon, Silva, &
Morliere, 2003; Fuentealba, Galvez, Alarcon, Lissi, & Silva, 2007; Masaki, Okano, & Sakurai,
1999; Ortwerth, Bhattacharyya, & Shipova, 2009; Wondrak, Jacobson, & Jacobson, 2006). All of
these fluorophores have very similar, overlapping spectral profiles and hence can be contributing
to the increase in fluorescence intensity with the time of glycation. However, fluorescence
lifetimes are highly dependent on the quantum yields and the lifetimes obtained from the fit might
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be from the tryptophan oxidation products (R. Borkman et al., 1980; R. F. Borkman & Lerman,
1978; R. F. Borkman et al., 1981; Burstein, Vedenkina, & Ivkova, 1973; Chen & Barkley, 1998;
Sauer, Hofkens, & Enderlein, 2011).
With excitation wavelength at 435 nm and an emission maxima between 500-510 nm, we do not
see the influence of tryptophan on the spectral profiles. However, we see a characteristic difference
in the fluorescence intensity between non-diabetic and diabetic lenses which follows the trend
observed in unmodified and glycated α-crystallin. Borkman et al have shown that by exciting the
aging non-diabetic lenses, a single lifetime of about 4.7 ns was observed which was consistent
with our results (R. Borkman et al., 1980; R. F. Borkman et al., 1981). By exciting the diabetic
lenses at 435 nm, we have observed that there is a significant difference in contribution and also
an occurrence of new lifetimes. The appearance of new lifetimes with increase in age or disease
progression in diabetic lens might be due to the formation of extensive AGE cross-links along with
other post-translational modifications. Characterization of the AGE fluorophores in this particular
spectral region is in progress.
Currently, the measurement of fluorophore lifetimes from the ocular fundus autofluorescence
(FAF) for clinical diagnostics is being investigated (D. Schweitzer, 2011). While, the fundus autofluorescence lifetimes are a valuable information, these values are dominated by contributions
from A2E, FAD and NADH which are characteristic of age-related macular degeneration
(Hammer et al., 2009; D. Schweitzer, 2011; Dietrich Schweitzer et al., 2004; D. Schweitzer et al.,
2012; D. Schweitzer, Hammer, & Schweitzer, 2005; D. Schweitzer et al., 2010). The autofluorescence emission from the crystalline lens itself acts as an obstruction for screening the fundus
and leads to decrease in fundus autofluorescence (FAF) signal due to back scattering (Velez &
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Weiter, 2002). On the other hand, the fluorescence lifetimes collected from the lens will be
primarily from AGE emission without any spectral interference from the connective tissue making
it an effective diagnostic tool for diabetes and other diseases associated with AGE formation.
Overall, we have been able to measure the fluorescence lifetimes of glycated α-crystallin as a
protein model and then observed similar consistent results in the human donor lenses. However,
the exact chemical nature of the dominant fluorophores when excited in the visible region still has
to be examined. In the future, specific AGE fluorophores which are excited in the visible region
from aging, non-diabetic and diabetic intact human donor eye lens will be determined. This will
help us to establish lens auto-fluorescence lifetimes as a very sensitive, non-invasive biomarker
for early diagnosis of diabetic eye diseases.
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CHAPTER 5 - OCULAR DRUG DELIVERY
General introduction
Ocular drug delivery has been a major challenge to pharmacologists and drug delivery scientists
due to the unique anatomy and physiology of the eye. Static and dynamic barriers in conjunction
pose a significant challenge for delivery of a drug alone or in a dosage form, especially to the
posterior segment. The main objective of drug delivery vehicles is to maintain the integrity of the
drug while achieving a slow release over an extended period of time. Ocular barriers render the
eye impervious to the entry of foreign substances. It is a challenge for the formulation scientist to
bypass these protective barriers of the eye so that the drug reaches the target site in desirable
concentrations. The pre-corneal constraints responsible for poor ocular bioavailability of
conventional ophthalmic dosage forms are solution drainage, lacrimation, tear dilution, tear
turnover & conjuctival absorption (Saettone, 2002).
Drug solution drainage is the most significant factor in reducing the contact time of the drug with
the cornea & consequently ocular bioavailability of topical dosage forms. The instilled dose leaves
the pre-corneal area within 2 minutes of instillation (Venkatesh, Kamlesh L, & Pramod Kumar,
2013). Most of the drug instilled in the form of eye drops is rapidly lost through the nasolacrimal
drainage (Mitra, 1993). The drug washed away by tears passes through the nasal mucosa into the
systemic circulation. Once the drug passes through the cornea into the eye, it has various barriers
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based on the polarity of the drug. The final concentration that reaches the target site is very low
requiring multiple doses of the drug (Fig 40).

Figure 40– Problems with conventional ocular drug delivery
(Maurice, D.M. (2002) Drug delivery to the posterior segment from drops. Survey Ophthalmol.)
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Table 16 - Disadvantages of conventional drug delivery systems
(Thakur & Kashiv, 2011)

Conventional drug delivery system

Disadvantages

Eye drops

Spillage from eye and overflow on eyelids

Eye ointments

Interference with vision

Ophthalmic gels

Less interference with vision but causes matted
eyelids

Out of the different novel drug delivery systems we investigated, liposomes are an excellent choice
for sustained-release ocular drug delivery because of their amphiphilic and non-toxic nature,
versatility and their ability to carry diverse chemical payloads. But, the conventionally prepared
liposomal formulations have several disadvantages. The first major problem is the stability and
low shelf life. These can be attributed to the fact that the phospholipids which form these liposomes
are highly prone to oxidation and hydrolysis. Also liposomes have a tendency to fuse together,
increasing the particle size as seen in Fig 41 and further cause light scattering.
Another major problem with the liposomes is the encapsulation efficiency. This depends on the
concentration of cholesterol used to stabilize the phospholipid bilayers (Fig 42). High
concentration of cholesterol leads to very inflexible bilayers leading to very low encapsulation and
very slow release. On the other hand, low concentration of cholesterol causes very high
encapsulation but very fast release. So, in order to overcome these disadvantages, there is a need
to engineer the liposomal formulations to have higher stability, very low drug leakage, high
encapsulation and slow release of the drug.
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Figure 41- Fusion of liposomes to form large aggregates (www.pharmainfo.net)

Figure 42 - Effect of cholesterol on the drug encapsulation and release
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Preformulation studies and method development
Introduction
The specific aim of this project was directed at understanding as well as determining the role of
composition variation, presence of adjuvants, surface modifications and methods of preparation
on the structural stability of the liposomes. Generally, liposomes are composed of natural and/or
synthetic phospholipids. Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) are the two
major structural components of most bio-membranes. Cholesterol has been largely used to improve
the bilayer structural characteristics of the liposomes (Vemuri & Rhodes, 1995). It improves the
membrane fluidity, bilayer stability and also reduces the permeability of hydrophilic molecules
through the membrane and hence providing a controlled release of drugs encapsulated within the
core of the liposomes. Lipid oxidation, hydrolysis and peroxidation have been described as
important degradation processes of fatty acyl groups on the component phospholipids (Chatterjee
& Agarwal, 1988; Konings, 1984; Laguerre, Lecomte, & Villeneuve, 2007; Niki, Yamamoto,
Komuro, & Sato, 1991; Samuni, Lipman, & Barenholz, 2000; Zhang & Pawelchak, 2000). Yin et
al have studied the influence of temperature, pH and phospholipid composition on the
phospholipid oxidation in the liposomes (Yin & Faustman, 1993). We used the information and
the compositions from the above references as our models and studied the effect of modifications
on their formulations.
Samuni et al have shown that the poly unsaturated fatty acid chains on the phospholipids are the
most sensitive component of the liposome bilayer to oxidative damage during long-term storage.
They have also shown that the presence of cholesterol in the liposomes provides protection to the
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lipid bilayers by decreasing the degree of hydration. Also, they have shown that the presence of a
water soluble anti-oxidant also helps to prevent the oxidative and hydrolytic degradation of the
lipid bilayers (Samuni et al., 2000). Crowe et al have investigated the effect of the presence of
sugars on liposome stability (J. H. Crowe et al., 1988; L. M. Crowe, Crowe, Rudolph, Womersley,
& Appel, 1985; Lois M. Crowe et al., 1986). They have shown that sugars prevent leakage of the
drug from liposomes during freeze-drying. It was reported that the mass ratio of carbohydrate to
the lipids as well the osmotic balance helps in preventing solute leakage (Alonso-Romanowski,
Biondi, & Disalvo, 1989). Calorimetric studies suggest that sugars prevent phase separation during
drying and phase transitions during rehydration and hence help in stabilizing the lipid bilayer (Lois
M. Crowe et al., 1986). We are working on determining the concentration of sugars and antioxidants to be included in our compositions to increase the stability without affecting the drug
release parameters.
Liposomes can be prepared by several different methods. The difference between the various
methods is the manner in which the lipids are dried from organic solvents and then redispersed in
aqueous media. The size and lamellarity of the liposomes obtained is different with different
methods (Laouini et al., 2012). There are numerous techniques for liposome preparation giving
rise to vesicles of different sizes ranging from nanometers to microns in diameter and different
lamellarity. However, most of these techniques are not suitable for the encapsulation of sensitive
substances because of their exposure to mechanical stresses, potentially harmful chemicals like
organic solvents and detergents or low/high values of pH during the preparation (Mozafari, 2005;
Riaz, 1996). Use of conventional methods like lipid hydration and extrusion give a very good
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encapsulation of the drugs but they are highly unstable. More novel methods involve exposing the
encapsulated compounds to organic solvents at high temperature.
The major aspect to consider in the preparation of liposomes is that lipid/phospholipid membranes
form as a result of unfavorable interactions between lipids/phospholipids and water molecules.
Thus, our emphasis in making liposomes is not towards the formation of lipid bilayers, but towards
getting the membranes to properly form vesicles of the right size and structure, and to entrap
materials with high efficiency without leaking out of the liposome randomly. Our aim is to prepare
liposomes using a combination of one or more methods to have cumulative advantages and also
formulations for better and efficient drug delivery.
Results
This study is designed to aid in understanding the structure of liposomes in order to improve their
stability as well as drug release properties. All of the literature published to date using liposomes
as drug delivery systems have attributed their failure to lack of stability in the liposomes as well
as several other factors mentioned above. In our work, we have been able to observe the
fundamental issues with these studies. We used a trial and error based method to understand the
variations in the liposomes with changes in composition, addition of adjuvants, methods of
preparation, freeze thaw cycles and surface modifications. The best formulations were determined
based on the particle size, encapsulation efficiency and the time of drug release. We used a variety
of advanced methods - structural, spectroscopic, biophysical and biochemical assays in these
studies. Dynamic light scattering (DLS) was used to measure the particle size of the liposomes.
An average particle size of 100-200 nm was desirable. The surface morphology of the liposomes
was observed by imaging using Transmission electron microscopy (TEM). The encapsulation
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efficiency of the liposomes was calculated based on fluorescence from the fluorescent marker.
When the formulation exhibited required particle size and optimum encapsulation efficiency, we
used these formulations for the dye release studies using a standard USP4 SOTAX dissolution
apparatus to determine the time of release. All of our proposed studies include a combination of
the above methods and helped us to understand the basics of liposome chemistry, hence making
our study innovative especially in the field of ocular drug delivery. We have investigated several
factors that affect the stability of the liposomes as follows:
A) Role of phospholipid composition in the stability of liposomes (Fig. 43- blue spheres)
The effect of lipid composition on the size and stability of the liposomes have been examined by
preparing liposomes with different molar ratios of phospholipids. We can observe that the molar
ratio of cholesterol was kept constant. The liposomes with high concentrations of
phosphatidylcholine formed the optimum size of 100-200 nm. On the other hand, the compositions
with high concentration of phosphatidylglycerol were found to promote fusion and an overall
increase in particle size. This can be attributed to the oxidation of unsaturated fatty acids on
phosphatidylglycerol. From this study, we can infer that the lower the concentration of
phosphatidylglycerol, the lower the chance of oxidation of the liposomes, thereby, increasing the
stability and shelf life.
B) Role of cholesterol composition in the stability of liposomes (Fig. 43 – green spheres)
Dynamic light scattering (DLS) measurements that the liposomes with less cholesterol tend to be
comparatively larger, on average, than liposomes with high cholesterol content. But, at the same
time, in our further studies, we have observed that the higher concentration of cholesterol prevents
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the encapsulation of the encapsulated marker. So, an optimum concentration of cholesterol is
required to have stable bilayers as well as optimum release. From our study, we have determined
that use of 25-30 % molar ratio of cholesterol with 70-75% molar ratio of total phospholipid
content gives very stable formulations.
C) Role of methods of preparation in the stability of liposomes (Fig. 43)
Conventional liposome preparation techniques were used to prepare the liposomes. The efficiency
of these methods was determined based on the resulting particle size, encapsulation efficiency and
the time of release of encapsulated marker (fluorescein).The different methods of preparation used
were – a) lipid hydration and extrusion method, b) sonication method, c) reverse phase evaporation
method and d) cryoprotectant freeze thaw method. From our preliminary studies, we determined
the best formulations with optimum particle size and encapsulation efficiency. The lipid hydration
and extrusion method gave moderate encapsulation and favorable particle size. However, the
liposomes start to fuse and leak the marker. In the case of mannitol freeze thaw method, the particle
size was small and also the liposomes showed very good encapsulation. Unfortunately, this method
produces liposomes that leak the solute at a very fast rate due to osmotic imbalance inside and
outside the liposomes. As an alternative, a modified method was used where both the lipid
hydration and extrusion methods as well as the mannitol freeze thaw method were combined. We
were able to get good particle size as well as very good encapsulation. For further studies, this
modified method will be the preferred method for encapsulating drugs and studying their potential
as ocular drug delivery systems.
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D) Role of anti-oxidants in the stability of liposomes
Canthaxanthin and beta-carotene were used as anti-oxidants to prevent the fusion of liposomes due
to oxidation. We have observed a large difference in the particle size of liposomes at different
phospholipid and cholesterol concentrations in the presence and absence of the anti-oxidants as
seen in Fig 44.
E) Role of cryoprotectant sugars in the stability of liposomes
A variety of sugars have been shown to act as protectants during dehydration/rehydration of
liposomes (L. M. Crowe et al., 1985; Janoff, 1998; Madden et al., 1985). This protective ability
can extend to prevent vesicle fusion and also help in improved encapsulation of the marker within
the liposomes. From our study, we have observed that 350 mM of mannitol and 175 mM of
trehalose give the best results in maintaining the stability during lyophilization. Small angle X-ray
scattering studies using these liposomes were performed at angles of 0.002 – 0.02 A° and the
scattering profiles in this region can be seen as in Fig 45. From the data obtained, we can explain
that the low angle scattering from cryoprotectant freeze dried liposomes might be due to interaction
of mannitol with the lipid bilayers and also the diffusion of mannitol between the inner and outer
hydrophilic layers helping in creating an osmotic balance.
F) Role of PEGylation in the stability of liposomes:
PEGylation of the liposomes did not have any effects on the particle size or the encapsulation
efficiency as seen in Fig 46. However, PEGylation makes the liposome surface more stable and
also improves the morphology of the liposomes. We observed that the liposomes were
homogenous with a low standard deviation in the size distribution profile. Also, it has an added
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advantage of increasing the immunogenicity of the drug carrier vehicle making this kind of surface
modification a good choice for sustained release of drugs over longer periods of time.
G) Model for stable liposomal formulations:
Using the information from all the preliminary stability studies based on particle size and
encapsulation efficiency, we downsized our formulations to three with the PC: PE: PG: cholesterol
compositions of 60:10:30, 65:5:5:25 and 60:5:5:30. Also we used fluorescein as a model small
molecule to test the rate of drug release from these formulations. From the studies, we have
observed that the liposomes were in the particle size of 100-200 nm and had a release over a period
of 2-3 months (Fig. 47 and 48).
Discussion
Use of colloidal dosage forms for ocular drug delivery has been highly exploited due to the
versatility of the formulations.(R. Gaudana, Jwala, Boddu, & Mitra, 2009) These dosage forms
include liposomes, nanoparticles, microemulsions, and nanoemulsions etc. Inadequate drug levels
reaching the target sites necessitate frequent drug administration. Ali et al have provided an insight
into the various disadvantages associated with ocular drug delivery and use of colloidal delivery
systems, i.e. nanoparticles, nanosuspensions, liposomes, niosomes, dendrimers and contact lenses
containing nanoparticles to deliver ocular drugs to the target sites.(Ali, Fazil, Qumbar, Khan, &
Ali, 2014).
Poor bioavailability of ocular drugs is mainly due to the washing away by tears, short lived
residence time, and impermeability through corneal epithelium.(Kaur, Garg, Singla, & Aggarwal,
2004) The topical and localized application are still an acceptable way to achieve therapeutic level
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of drugs used to treat ocular disorders but the primitive ophthalmic solution, suspension, and
ointment dosage form are no longer sufficient to combat various ocular diseases. Incorporation of
liposomes in ophthalmic drug formulations enables improved ocular bioavailability of the drug
and its protection from enzymes present on the surface of corneal epithelium. Active ingredients
for which liposomal ophthalmic drug forms are being developed include anti-viral agents like
acyclovir and ganciclovir (Seyfoddin & Al-Kassas, 2013); antibiotics like chloramphenicol and
ciprofloxacin (Hosny, 2010); anti-glaucoma agents like pilocarpine and acetazolamide. (Budai et
al., 2007; Kaur et al., 2004).
Liposomes (also known as bilayer lipid vesicles) are ideal models of cells and biomembranes.
Their resemblance to biological membranes makes them an ideal model for the study of drug
transport, which can be fine-tuned to act as non-toxic, biodegradable drug delivery systems
(Bangham, Hill, & Miller, 1974). Liposomes are composed of one or more concentric or nonconcentric phospholipid bilayers and can be used to entrap small molecules and proteins in their
structure. They can be either unilamellar or multilamellar and can accommodate hydrophilic,
lipophilic and amphiphilic compounds in their aqueous and/or lipid compartments. On the basis
of many studies, involving reducing liposome size and obtaining good encapsulation of the drugs,
small (100–200 nm) “conventional” liposomes composed of neutral lipids and cholesterol have
been prepared.
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Figure 43– Pre-formulation screening for ideal formulations
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Figure 44- Effect of canthaxanthin and beta carotene on the particle size of the liposomes after
30 days in solution
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Figure 45 – SAXS data from liposomes with and without mannitol as Cryoprotectant
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Figure 46 - Effect of PEGylation on the particle size and encapsulation efficiency of the
liposomes
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Figure 47- TEM image of liposomal formulation 60:5:5:30, 65:5:5:25 and 60:10:30 with
encapsulated fluorescein
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Figure 48- Dye release profiles of liposomal formulations with molar ratios of PC:PE:PG:Chol at
60:5:5:30, 65:5:5:25 and 60:10:30 with fluorescein as the marker

An ideal liposomal formulation should have the following characteristics – a) minimal rate of
leakage of the marker, b) metabolically inert and c) biodegradable. While the liposomes are nontoxic and biodegradable owing the phospholipid infrastructure, they are highly prone to oxidation
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and hydrolysis making them very unstable. This is a major disadvantage for using liposomes as
drug delivery systems which overcomes the fact that they can be compartmentalized to delivery
drugs of varying polarities. So our efforts through this project were to overcome the problems and
develop stable formulations which we could use as our drug delivery system for controlled release
of the drug.
Some of the factors that play an important role in stability of the liposomes are size, charge, phase
transition and the presence of cholesterol. In case of ocular drug delivery systems, the ideal size of
the liposomes is about 100-200 nm. This helps in increasing the drug payload as well as prevents
the scattering of light that enters the eye. Ostro et al and Senior have shown that the use of charged
phospholipids decreases the overall stability of the liposomes by increasing the fusion (Ostro;
Senior, 1986). Blok et al have explained the importance of phase transition and its effect on size
and permeability of the liposomes. They have shown that use of high phase transition
phospholipids like phosphatidylcholine would give more favorable results compared to low phase
transition phospholipids like phosphatidylserine (Blok, van der Neut-Kok, van Deenen, & de Gier,
1975).
Another important factor that determines the stability of the liposomes is the presence or absence
of cholesterol. Cholesterol inserts into bilayer membranes with its hydroxyl group oriented toward
the aqueous phase and its hydrophobic ring system adjacent to fatty acid tails of phospholipids.
The hydroxyl group of cholesterol forms hydrogen bonds with the polar phospholipid head groups.
Interaction with the relatively rigid cholesterol decreases the mobility of hydrocarbon tails of the
phospholipids. But the presence of cholesterol in a phospholipid membrane interferes with close
packing of fatty acid tails in the crystal state, and thus inhibits phase transition. Phospholipid
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membranes with a high concentration of cholesterol have a fluidity ranging between that of the
liquid crystal and crystal states (Cho, Dominick, & Spence, 2010; Dai, Alwarawrah, & Huang,
2009; de Meyer & Smit, 2009; Samuni et al., 2000; Zhang & Pawelchak, 2000).
The next problem to be dealt in the liposomes was oxidation and hydrolysis. Phosphatidylglycerol
(PG) has a readily oxidizable group at the polar head region and easily prone to oxidation. To
overcome this disadvantage, we incorporated hydrophobic anti-oxidants within the formulations
containing PG to be embedded in the lipid bilayers, thereby, preventing the oxidation. Out of the
different anti-oxidants used, beta carotene and canthaxanthin have given the best results. However,
canthaxanthin had to be discarded owing to its toxicity in the eye (Sujak, 2009). Beta carotene, on
the other hand, is non-toxic and was also found to help in maintain the integrity of the lipid bilayers
under oxidative stress (R. Liang et al., 2012). Socaciu et al have shown that beta carotene had good
anti-oxidant activity even at low concentrations. They have also determined that it had a tendency
to localize within the lipid bilayers increasing the overall hydrophobicity and decreasing the water
permeability of the lipid bilayer thereby preventing hydrolysis (Socaciu, Bojarski, Aberle, &
Diehl, 2002).
Though, we determined the concentration of cholesterol and beta carotene to prevent oxidation
and hydrolysis of the lipid bilayer, we still had the problem of storage of the liposomes to increase
the shelf life. This potential problem was solved by lyophilizing the liposomes and storing them
as a powder. But, lyophilization of liposomes promotes fusion and a concomitant increase in
capture volume due to freeze fracture at extremely low temperatures. To avoid this problem, we
used cryoprotectant sugars with non-eutectic behavior. Cryoprotectants slow down the ice crystal
formation allowing water to freeze as an amorphous glass with the liposomes dispersed
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throughout. Many groups have reported that even at high concentrations of the cryoprotectants,
they could still observe about 20% of leakage (J. H. Crowe et al., 1988; L. M. Crowe et al., 1985;
Lois M Crowe, Reid, & Crowe, 1996; Lois M. Crowe et al., 1986; Date, Samad, & Devarajan,
2010; Rudolph, 1988; Rudolph & Goins, 1991; Suzuki & Komatsu, 1996). However, we have been
able to restrict the leakage to less than 8% by increasing the overall hydrophobicity of the liposome
lipid bilayers by incorporating a hydrophobic anti-oxidant.
Our step by step approach has helped us to deal with one problem at a time thereby helping us to
overcome the issues with the liposomes. Overall, we have been successful in developing very
stable liposomal formulations with a slower drug release. This formulation technology was used
to develop model drug delivery systems that may be useful for treating ocular diseases especially
endophthalmitis, diabetic retinopathy and wet age related macular degeneration.
Controlled release drug delivery to prevent infection and inflammation after cataract surgery
Introduction
Cataract is an age related clouding of the eye lens which gradually leads to loss of vision. Cataracts
are very common in older people and the leading cause of blindness all over the world as seen in
Fig 49. By age 80, most people either have a cataract or have had cataract surgery. In a normal
eye, light passes through the cornea and the transparent lens focuses it onto the retina. Once it
reaches the retina, light is changed into nerve signals that are sent to the brain. Transparency of
the lens plays an important role in the sharpness of the image received by the retina. The lens
becomes more opaque/cloudy with the development of a cataract making the image blurry.
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The symptoms of early cataract may be improved with new eyeglasses, brighter lighting, anti-glare
sunglasses, or magnifying lenses. If these measures do not help, surgery is the only effective
treatment. Surgery involves removing the cloudy lens and replacing it with an artificial lens called
the intraocular lens (IOL). If the subject has cataracts in both eyes that require surgery, the surgery
will be performed on each eye at separate times, usually four to eight weeks apart.
As with any surgery, cataract surgery comes with risks such as infection and bleeding. After the
surgery, it takes around 4-6 months for the eye to regain its natural immunity. During this recovery
period, the eye is highly susceptible to various bacterial and fungal infections, termed
endophthalmitis, which ultimately leads to blindness (West, Behrens, McDonnell, Tielsch, &
Schein, 2005). It has been reported that around 0.3% of the patients who had cataract or any kind
of invasive ocular surgery develop the infection (Klotz, Penn, Negvesky, & Butrus, 2000).
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Figure 49- Global cause of blindness
(Reference: State of world’s eyesight preview)
The most common form of treatment for infection is administration of antibiotics in the form of
eye drops. However, drug delivery through eye drops is not efficient due to the problems with
permeability through different ocular barriers. By the time the antibiotic has penetrated to the
vitreous humor the available amount has decreased to less than one percent of the original
concentration (Mamalis, Kearsley, & Brinton, 2002).
The main goal of this project is to develop an improved method to deliver antibiotics to prevent
infections that result from invasive ocular surgeries especially cataract surgery. There have been
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several groups that have worked on developing drug coated intraocular lenses and currently, there
are drug-eluting lenses available in the market. However these do not have a controlled drug
release (Ali et al., 2014; Ciolino et al., 2009; Ciolino et al., 2011; Galin, 1980, 1988; R. Gaudana
et al., 2009; González-Chomón, Concheiro, & Alvarez-Lorenzo, 2011; Heyrman, McDermott,
Ubels, & Edelhauser, 1989; Lim et al., 2001; Nishi, Nishi, Yamada, & Mizumoto, 1995; Wong,
Hu, & Berger Jr, 2001).
Advances in coating technology can be seen in the work published and patented in the past few
years for controlled drug delivery to treat infective diseases as well as inflammation (Fu-Giles,
2013a, 2013b, 2013c; Gulsen & Chauhan, 2004; Gulsen, Li, & Chauhan, 2005; Hoch, Chauhan,
& Radke, 2003; Kapoor, Thomas, Tan, John, & Chauhan, 2009; Kim, Conway, & Chauhan, 2008;
Kim, Peng, & Chauhan, 2010; Peng & Chauhan, 2011; Peng, Kim, & Chauhan, 2010). Their work
has helped us to understand the use of biodegradable polymer coatings as a means of controlled
release of drugs.
Based on the literature, we selected a few biodegradable polymers for coating our intraocular
lenses. But most of these polymers had to be dropped as potential candidates owing to their ocular
toxicity. Poly- lactic glycolic acid (PLGA) was found to be the best candidate to act as a drug
depot which had to be tested further. We tested other mucoadhesive polymers as potential
candidates. However, they would not adhere to the surface of the silicone lens due to its
hydrophobicity.
Results
A barrier that prevents the coating of the lenses is that they are composed of silicones that prevents
hydrophilic solutions from adhering. In order to modify the hydrophobicity and allow for the
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liposome coating, oxygen plasma treatment was used. In this method, the surface of the lens is
temporarily modified by turning the silicon dioxide into silanol groups (Fig 50). The hydrophilic
surface of the lens however is transient and lasts approximately 15-20 minutes. During this time,
a primary coating of PLGA containing the drug is coated on to the lens using spin coating. PLGA
is a hydrophilic polymer that is biodegradable and FDA approved.
Different coatings containing PLGA and PEG as a plasticizer were used as seen in the Fig 51. The
most efficient one was determined by using fluorescein in the PLGA and PEG coating solutions
and visualizing the fluorescence using confocal laser scanning microscopy (CLSM). The most
uniform coating was found to be the PLGA solution with 1% PEG. Using this coated lens, a
secondary coating was applied again by spin coating. The basic requirement for the secondary
coating was that the polymer had to be biodegradable and forms a hydrogel which releases the
liposomes upon swelling. In order to find the most suitable coating three polymers were tested,
which included methyl cellulose, hydroxyl propyl cellulose, and hyaluronic acid. To these
solutions, rhodamine was added and the fluorescence intensity measurement using a dual scanning
system was used to construct the topography on the lens. The imaging of the secondary coatings
appear in Figure 52. Based on the images and considering the time of sample preparation, we
concluded that hyaluronic acid and hydroxyl propyl cellulose gave the best results in terms of
uniform coatings.
Finally for our drug release studies, we coated the silicone lenses with PLGA containing the marker
(fluorescein) and let it vacuum dry for 2 days to remove any traces of organic solvents. Then it
was further coated with a secondary coating solution of the mucoadhesive polymer with
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fluorescein entrapped liposomes. These final products were again dried under vacuum and tested
for the drug release profiles as seen in Fig 53. A summary of the coatings is given in Table 17.

Figure 50- Use of oxygen plasma for surface plasma treatment of the silicone lens and the
corresponding atomic force microscopy images
Reference: (Jiyeon Lee, Kim, & Lee, 2006)
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Figure 51 - Primary coating with PLGA containing the marker
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Figure 52- Secondary coating with different mucoadhesive polymers containing rhodamine as a
marker
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Table 17 - Summary of composition of coatings
SAMPLE

PROCESS

1

Fluorescein entrapped liposomes; no coating

2

Fluorescein in PLGA coating; no liposomes

3

Fluorescein in PLGA
coating

Fluorescein trapped liposomes in HPMC
coating

4

Fluorescein in PLGA
coating

Fluorescein trapped liposomes in HA
coating

Conventional liposomes used in this case released the encapsulated fluorescein over a period of 30
days. Uncoated fluorescein-PLGA films showed drug release with linear kinetics for 50 days,
releasing fluorescein in the film, with no release thereafter. Coating of the fluorescein-PLGA film
with HPMC (hydroxyl propyl methyl cellulose) entrapped liposomes resulted in significantly
slower and longer release kinetics, providing about 4 months of release with zero-order kinetics.
This might be due to the fact that HPMC doesn’t form a hydrogel and is readily soluble in aqueous
environment releasing the liposomes. On the other hand, fluorescein PLGA film coated with HA
(hyaluronic acid) showed a further slower release over a period of 6 months. Hyaluronic acid is
biodegradable, viscoelastic and has good water binding ability making it an ideal biopolymer for
coating the silicone intraocular lenses.
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Figure 53- Drug release profiles from conventional liposomes, PLGA coated lens, PLGA coated
lens with HPMC containing liposomes and PLGA coated lens with HA containing liposomes
Discussion
The field of drug delivery through intraocular lenses has begun a rapid pace of exploration and
study. Researchers in this field have been investigating different materials to extend the release
time of pharmaceuticals from these lenses. The drug eluting lenses available in the market do not
have the controlled drug release required to prevent frequent administration of the drugs. The
strategy used right now for manufacturing these lenses is by modifying the base material right at
the polymerization process. In the technique of molecular imprinting, high affinity cavities are
created within the material by polymerizing in the presence of a template. These cavities serve to
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retard the diffusion of the loaded drug, which closely resembles the template. However, this
process can only help retain the drug for a short interval of time. We developed a prototype lens
coating technology that has prolonged drug release and can be used for multidrug therapy.
In our study, we used plasma treatment to modify the surface of the silicone lenses to make it
convenient for coating the drug and drug encapsulated liposomes. Secondly, the method of drug
loading on the lens can also be varied to affect release times. The drug can be encapsulated at a
high concentration within a thin film coating on the silicone surface. The film serves as a drug
reservoir that must be eroded from the lens surface by the ocular fluid circulation. Finally, the drug
can also be loaded and attached to the silicone lens surface using drug encapsulated liposomes in
a mucoadhesive polymer matrix providing another barrier to drug diffusion and transport.
Overall, the surfaces of commercially available intraocular lenses can be coated so that they
prevent the rapid diffusion and loss of the drug making them ideal drug delivery systems to prevent
endophthalmitis. Our study has shown that the use of coatings or diffusion barriers has been
successful in prolonging the release time of small molecules from prototype silicone lenses.
Sustained-release drug delivery for treatment of ocular angiogenesis
Introduction
Ocular angiogenesis is a serious complication in the eye mainly observed in the retina and the
choroid. Angiogenesis is characterized by the growth of new blood vessels into the retina
damaging its surface in the process. The new blood vessels are fragile, “leaky” and pool blood into
the retinal space, further damaging the retina. Angiogenesis depends on cell adhesion and
proteolytic mechanisms that involve the activity of growth factors, extracellular matrix proteins,
proteases and adhesion molecules (Bischoff, 1997). New fragile blood vessels form either by
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sprouting angiogenesis, where vascular endothelial cells proliferate and migrate into the
extracellular matrix (Ausprunk & Folkman, 1977), or by intussusceptive angiogenesis, where
transcapillary pillars are formed and partition the vessel lumen (Caduff, Fischer, & Burri, 1986;
Filipovic et al., 2009) or by looping angiogenesis, where blood vessels translocate by
biomechanical forces (Benest & Augustin, 2009; Kilarski, Samolov, Petersson, Kvanta, &
Gerwins, 2009).
Laser treatments and drugs like Lucentis and Avastin are available for controlling the diseases
(Pieramici & Rabena, 2008). These drugs are anti-VEGF antibodies that inhibit the growth of new
blood vessels. Avastin is designed to directly bind to VEGF extracellularly to prevent interaction
with VEGF receptors (VEGFRs) on the surface of endothelial cells, and thereby may inhibit
VEGF's angiogenic activity. Lucentis is a recombinant humanized monoclonal antibody fragment
(lacking an Fc region) as seen in Fig 54. Lucentis is the first VEGF inhibitor specifically designed
for use in the eye to bind to and inhibit VEGF-A, thereby, preventing angiogenesis and
hyperpermeability of the blood vessels (Gaudreault et al., 2007; Herbst et al., 2007; Melnikova,
2005; Wujcik, 2014).
The main advantages of protein drugs as therapeutic agents are their target specificity, strong
affinity, bio-reactivity and low toxicity making them excellent choice for treatment of metabolic
disorders. A disadvantage is that after administration of high concentrations of proteins in the eye,
they tend to precipitate and lead to adverse reactions. Other challenges faced by protein drugs in
the eye are their susceptibility to enzymatic degradation, short vitreous half-life, ion permeability,
immunogenicity, post-translational modifications, aggregation and denaturation.

140

The intravitreal injections (Fig 55) administered every month are inconvenient and very expensive
(Rosenfeld, 2006; Steinbrook, 2006). It has also been shown that the risk of infectious
endophthalmitis increases due to frequent injection of antiangiogenic agents (Diago et al., 2009;
Englander, Chen, Paschalis, Miller, & Kim, 2013; Ranchod et al., 2010). In order to overcome the
disadvantages as well as increase the patient compliance, we are trying to encapsulate the protein
drug in nanostructures, prolong the time of drug release into the eye, thereby, decreasing the
frequency as well as the cost factor for these treatments.

Figure 54– Structural comparison of Avastin and Lucentis
(http://www.arizonaretinainstitute.com/treatment-of-wet-macular-degeneration-arizona.html)
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Figure 55- Cost estimates of Lucentis and Avastin per injection
(http://www.scienceofamd.org/treat)
Traditional methods used for encapsulation of proteins have been less stable or have very low
encapsulation efficiency (Martins, Sarmento, Ferreira, & Souto, 2007). Abrishami et al have been
able to observe a sustained release of the anti-VEGF drugs up to a period of 42 days (Abrishami
et al., 2009).

They have shown that the intravitreal injection of liposome encapsulated

bevacizumab (Avastin) was well tolerated through 42 days in rabbits and the clearance of this drug
from the vitreous with liposomal formulations was slower than the soluble form. However, they
were not able to restrict the fast release of the protein into the vitreous. One of the aims of our
work is to encapsulate the antibodies within the liposomes and slow the rate of amount released.
Results
The strategy of delivering proteins to ocular compartments using carriers represents the most
promising approach to improve protein bioavailability. Lucentis and Avastin are given as monthly
injections and hence increase the risk of infection. Our current study deals with the design and
optimization of liposomes to address the problems of encapsulating proteins as well as protecting
them from degradation. Our interest in this research project was to encapsulate the protein drug in
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our stable liposomal formulations, prolong the time of drug release into the eye, thereby,
decreasing the frequency as well as the cost factor for these treatments.
Fluorescein tagged human serum albumin and Immunoglobulin G were used as a model proteins
to study the encapsulation and drug release of the protein. The method we used for the
encapsulation of fluorescein tagged proteins was a combination of lipid hydration, extrusion and
mannitol freeze thaw methods. The human serum albumin and IgG used as protein models as they
were close in molecular weight to Lucentis and Avastin respectively.
Our conventional liposomal formulations were able to overcome the stability problems by
preventing the lipid bilayer fusion as well as increasing the time of drug release (Fig 56, 57 and
58).
Conventional liposomes when administered in vivo, fuse with the cell membranes spontaneously
releasing the encapsulated drugs. In order to prevent the spontaneous release of drug and to further
extend the time of release to around 6 months, stealth liposomes were prepared by surface
modification of the liposomes using PEGylation method. The size of the liposomes was then
measured using dynamic light scattering as shown in Fig 59. The encapsulation efficiency (Fig 59)
was determined based on the fluorescence of the tag on the protein. TEM images of the
formulations are also displayed in Fig 60. The drug release studies were performed using the
SOTAX USP 4 dissolution apparatus and the results are presented in Fig 61.
As human serum albumin is a globular protein, it cannot exactly replicate the surface
characteristics of antibodies. So, the studies were repeated using fluorescent tagged
immunoglobulin G (IgG) as a marker to model the encapsulation of antibodies in the liposomes.
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The particle size, encapsulation efficiency, surface morphology and the drug release studies from
liposomes encapsulating IgG are presented in Fig 62, 63 and 64 respectively.

Figure 56- Particle size measurements and encapsulation efficiency of conventional liposomes
encapsulating fluorescent tagged human serum albumin.
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Figure 57 - TEM image of conventional liposomes with molar ratios of PC:PE:PG:Chol at
60:5:5:30, 65:5:5:25 and 60:10:30 with encapsulated HSA
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Figure 58- Drug release profiles of conventional liposomes with encapsulated HSA at
formulation molar ratios of PC:PE:PG:Chol at 60:5:5:30, 65:5:5:25 and 60:10:30
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Figure 59- Particle size measurements and encapsulation efficiency of stealth liposomes
encapsulating fluorescent tagged human serum albumin
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Figure 60- TEM image of stealth liposomes 60:5:5:30, 65:5:5:25 and 60:10:30 with encapsulated
human serum albumin

148

Figure 61- Drug release profiles of long circulating or stealth liposomes with encapsulated
fluorescein tagged human serum albumin
Molar ratios of PC:PE:PG:Chol at 60:5:5:30, 65:5:5:25 and 60:10:30
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Figure 62- Particle size measurements and encapsulation efficiency of stealth liposomes
encapsulating fluorescent tagged Immunoglobulin G
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Figure 63- TEM image of stealth liposomes 60:5:5:30, 65:5:5:25 and 60:10:30 with encapsulated
immunoglobulin G
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Figure 64– Drug release profiles of stealth liposomes using fluorescein tagged IgG as a marker
Molar ratios of PC:PE:PG:Chol - 60:5:5:30, 65:5:5:25 and 60:10:30

Discussion
Liposomes are microscopic vesicles composed of phospholipid bilayers that enclose aqueous
compartments. Liposome membranes are semi permeable and can thus be used as controlled
release systems. Proteins and oligopeptides are very large and charged; hence have a very restricted
movement across cell membranes .The main disadvantages with using liposomes as drug delivery
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systems is their stability, lower shelf life and leakage of drug. By engineering the composition and
method of preparation, we have been able to produce stable liposomes and hence an ideal vector
for delivery of the protein drugs.
Conventional liposomes are liposomes that do not contain any surface modifications. Although
the liposomes protect the encapsulated molecule from degradation, when administered into the
body, they are easily captured by the mononuclear phagocyte system and are removed from the
blood stream (Gregoriadis, 1995). The elimination of conventional liposomes is a great
disadvantage since their degradation prevents the drug from reaching its target zone. The removal
of the liposomes from circulation first begins when opsonin serum proteins attach to the surface.
These proteins mark the liposomes for degradation and allow the binding phagocytic cells to the
liposomes. In case of the eye, the liposomes fuse with the phagocytic cells readily releasing the
drug within a shorter interval of time.
Stealth liposomes were developed to correct these instability problems and their success has helped
renew interest in liposomal-targeted therapy. The lipid bilayer of stealth liposomes is coated with
long chains of polyethylene glycol, a hydrophilic polymer. This polymer produces a hydrated shell
around the external surface of the lipid bilayer, thus creating a steric barrier preventing interactions
with plasma proteins, opsonins, and cell surface receptors. Consequently, these liposomes are able
to evade the reticulo-endothelial system and remain in the circulation longer making them
excellent candidates for sustained-release drug delivery to treat angiogenesis (Janoff, 1998).
The association of drugs with vehicles like liposomes affects the in vitro pharmacokinetics of the
drugs. A marker (model for small molecule drug or biologics) when encapsulated within the
liposome is prevented from interacting with its target site until released from the liposome. When
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we are measuring the release of the marker from liposomes, we are looking at a combination of
pharmacokinetic mechanisms- a) the pharmacokinetics of the liposomal vehicle along with the
encapsulated marker and b) the pharmacokinetics of drug released from the liposomes. The rate of
release can be influenced by various parameters. When the marker is still encapsulated within the
liposome, it is biologically inactive, protected from degradation and hence the pharmacokinetics
depend entirely on the factors affecting the liposomes like diffusion, viscosity of the medium,
stability of lipid bilayers and osmotic balance. However, once the drug is released, it is affected
by the volume of distribution and degradation.
Targeting ocular angiogenesis is a promising approach to arrest diabetic retinopathy and wet
AMD. Nonetheless, due to a very low half-life of Lucentis and Avastin in the plasma, the
intravitreal injections have to be administered every month which is very expensive and painful.
It is also possible that multiple injections over the year can lead to secondary infections. Moreover,
as the eye is a unique organ protected via layers of different polarities, the drugs need to bypass
such barriers and reach the retina in a therapeutic dosage. Therefore developing drug delivery
platforms that bypass such barriers and target the therapeutics to the posterior segment of the eye
while still protecting the drug until it is released is a challenge. Our study dealt with the aspects of
increasing the stability of liposomes and increasing the payload of the protein marker in the
process. We have been successful in developing prototype formulations in vitro which were able
to prolong the time of release to about 200-240 days while preventing protein degradation until
release. Our technology has the potential to overcome disadvantages of current drug delivery
systems and pave way for a new and promising delivery platform to reach the clinical setting.
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CHAPTER 6 - CONCLUSIONS AND FUTURE DIRECTIONS
Non-enzymatic glycation of alpha crystallin as an in vitro model for aging and diabetes in the
lens
Alpha crystallin is the most abundant and largest of the lens proteins (~ 18 nm in diameter)
consisting anywhere between 30-40 subunits with molecular weight ranging from 800-1200 kDa.
In their native form, α-crystallin consists of two homologous subunits showing 55% sequence
similarity in a ratio of 3:1 - αA and αB, with 173 and 175 amino acid residues, respectively. The
molecular weight of these two subunits is approximately 20 kDa. αA crystallin is confined to the
lens with a small amount in the retina, spleen and thymus. αB crystallin is ubiquitously present in
the lens, retina and the heart abundantly, and is expressed under stress and pathological conditions
in the spinal cord, muscles, brain and the kidneys. Studies show that α-crystallins act as antiapototic regulators and prevent apoptosis under stress conditions, thereby protecting the tissues
from damage.
Our work dealt with investigating the effect of non-enzymatic glycation on alpha on the structure
of the protein. We found that the glycation of alpha crystallin causes protein denaturation, usually
associated with the formation of aggregates. Also we concluded that non-enzymatic glycation of
alpha crystallin leads to the loss of protein structural integrity. Loss of definite protein structure
associated with formation of aggregates leads to loss of function as a chaperone and anti-apoptotic
agent. This study, thereby, will prompt a need for studying diabetes models in order to understand
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the effect of protein aggregation in various degenerative diseases. This study will also increase the
awareness in the research communities to start studying the involvement or effect of diabetes in
cancers and degenerative diseases. In the future, attempts have to be made in determining the
quaternary structure of alpha crystallin.
Early diagnosis of diabetes through the eye
Alpha crystallin in the ocular lens is a small heat shock protein with no protein turnover. Hence, it
acts as a molecular chronograph for post-translational modifications especially non-enzymatic
glycation which forms fluorescent advanced glycation end-products (AGEs). We used steady state
and time resolved fluorescence measurements to study the spectroscopic changes in alpha
crystallin with increase in time of glycation. The AGE fluorescence lifetimes are extremely
sensitive to the local biochemical environments which differed in healthy and diabetic tissues. It
served as a baseline for discriminating fluorophores which trigger auto-fluorescence for the
detection of diabetic eye disease. Further, fluorescence measurements from non-diabetic and
diabetic human donor lenses matched the spectral profiles created using glycated alpha crystallin
as a model. Overall, our study helped us to establish a more precise diagnostic tool for early
detection of diabetes mellitus. In the future, attempts will be made to study the glycated proteome
observed as a result of diabetes mellitus. Also, more accurate methods have to be developed for
the characterization of the advanced glycation end-products which might help in developing
biomarkers for other diseases.
Ocular drug delivery
Drug delivery to the eye is complicated due to the presence of several ocular barriers. So, it is
necessary to develop novel drug delivery systems which would ensure slower drug release and
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more efficient treatment. After an ocular surgery, it takes about 4-6 months for the eye to regain
its natural immunity. In the meantime, the eye is very susceptible to various bacterial and fungal
infections, termed endophthalmitis, which results in blindness. In order to overcome this problem
and achieve a sustained release of drugs, we are developing a technology for coating ocular
medical devices like intraocular lenses and contact lenses with drug encapsulated liposomes.
Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD) are the most common
ocular diseases and a leading cause of blindness in American adults. Laser treatments and drug
intervention with Lucentis and Avastin are available for controlling angiogenesis. These drugs are
anti-VEGF antibodies that inhibit the growth of new blood vessels. The antibody injections are
given on a monthly basis into the eye and which are inconvenient, painful as well as very
expensive. We are working on encapsulating the protein drugs within the liposomes to obtain drug
release over a longer period of time, thereby decreasing the frequency and cost of the injections.
In order to treat the ocular disorders, we used liposomes to achieve a sustained release of drugs.
But, the conventional liposomal formulations have several disadvantages especially with stability
and low shelf life. Another major problem for liposomes is the encapsulation efficiency. All the
literature published to date have attributed their failure to lack of stability in the liposomes as well
as several other factors mentioned above. With our work, we have been able to observe and
overcome the fundamental issues in these formulations. We used a trial and error based approach
to understand the variations in the liposomes with change in compositions, addition of adjuvants,
methods of preparation, freeze thaw cycles and surface modifications. The best formulations were
determined based on the particle size, encapsulation efficiency and the time of drug release. These
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formulations were used in developing various ocular drug delivery systems based on the
requirement.
Liposomes as a slow release drug delivery system were employed to prevent infections that result
from ocular surgeries. The liposomes slowly release the drug into the eye and helps in preventing
infections over a period of 4-6 months during which the eye regains its natural immunity. One of
the goals of this study was to increase the lifetime of the liposomes in order to avoid multiple drug
administration. The second goal was to treat endophthalmitis and inflammation that results from
invasive ocular surgeries especially cataract surgery. In order to do this, artificial lenses were
coated with liposomes containing the drug. Currently there are drug-eluting lenses available in the
market, however they do not have a controlled drug release. The technology we developed helped
to control the dosage - the drug was incorporated in poly- lactic glycolic acid (PLGA) primary
coating and also a secondary hydrophilic muco-adhesive coating matrix embedded with drug
encapsulated liposomes. By using this method, the amount of drug administered was controlled
and quantifiable. This model drug delivery system can be used in a clinical setting to prevent the
development of any infections after a cataract surgery.
Angiogenesis observed in diseases like diabetic retinopathy and wet age-related macular
degeneration is characterized by the growth of new blood vessels into the retina damaging its
surface in the process. The anti-VEGF intravitreal injections, administered every month are
inconvenient as well as very expensive. Our interest in this research project was to encapsulate the
protein drug in nanostructures, prolong the time of drug release into the eye, thereby, decreasing
the frequency as well as the cost factor for these treatments. Currently, we have been successful in
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encapsulating a model protein into our stable liposomal formulations and attain a controlled release
over a period of 6-8 months in vitro.
In the future, we are interested in encapsulating the protein drugs- Avastin and Lucentis to show
the efficiency of our drug delivery vehicle. With this study, our efforts would be to decrease the
frequency of intravitreal injections from 12 to 2 per year, thereby effectively making the treatment
more economic.
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